



HU000030062T2

(19) **HU****MAGYARORSZÁG****Szellemi Tulajdon Nemzeti Hivatala**(11) Lajstromszám: **E 030 062**(13) **T2**

EURÓPAI SZABADALOM SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 11 840392**(22) A bejelentés napja: **2011. 11. 08.**(51) Int. Cl.: **A61K 315/54** (2006.01)**A61P 1/16** (2006.01)

(96) Az európai bejelentés bejelentési száma:

EP 20110840392

(86) A nemzetközi (PCT) bejelentési szám:

PCT/SE 11/051335

(97) Az európai bejelentés közzétételi adatai:

EP 2637668 A1 **2012. 05. 18.**

(87) A nemzetközi közzétételi szám:

WO 12064266

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 2637668 B1 **2016. 05. 11.**

(30) Elsőbbségi adatok:

410957 P **2010. 11. 08.****US****1051165** **2010. 11. 08.****SE**

(73) Jogosult(ak):

Albireo AB, 413 46 Göteborg (SE)

(72) Feltalálók:

GILLBERG, Per-Göran, 431 69 Mölndal (SE)**GRAFFNER, Hans, 252 84 Helsingborg (SE)****STARKE, Ingemar, 413 01 Göteborg (SE)**

(74) Képviselő:

Olle Bäcklund, Spanga

(54)

IBAT inhibitorok májbetegségek kezelésére

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 637 668 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
11.05.2016 Bulletin 2016/19

(21) Application number: **11840392.2**

(22) Date of filing: **08.11.2011**

(51) Int Cl.:
A61K 31/554 ^(2006.01) **A61P 1/16** ^(2006.01)

(86) International application number:
PCT/SE2011/051335

(87) International publication number:
WO 2012/064266 (18.05.2012 Gazette 2012/20)

(54) **IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES**

IBAT-HEMMER ZUR BEHANDLUNG VON LEBERERKRANKUNGEN

INHIBITEURS IBAT POUR LE TRAITEMENT DE MALADIES DU FOIE

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**
Designated Extension States:
BA ME

(30) Priority: **08.11.2010 US 410957 P**
08.11.2010 SE 1051165

(43) Date of publication of application:
18.09.2013 Bulletin 2013/38

(60) Divisional application:
15193953.5

(73) Proprietor: **Albireo AB**
413 46 Göteborg (SE)

(72) Inventors:
• **GILLBERG, Per-Göran**
431 69 Mölndal (SE)
• **GRAFFNER, Hans**
252 84 Helsingborg (SE)

• **STARKE, Ingemar**
413 01 Göteborg (SE)

(74) Representative: **Novitas Patent AB**
P.O. Box 55557
102 04 Stockholm (SE)

(56) References cited:
EP-A1- 1 535 913 WO-A1-03/022286
WO-A1-03/106482 WO-A1-2004/089350
WO-A1-2013/063512 WO-A1-2013/063526

• **PAUL ANGULO: "Use of ursodeoxycholic acid in
patients with liver disease", CURRENT
GASTROENTEROLOGY REPORTS, vol. 4, no. 1,
1 February 2002 (2002-02-01), pages 37-44,
XP055017235, ISSN: 1522-8037, DOI:
10.1007/s11894-002-0036-9**

Remarks:

The file contains technical information submitted after
the application was filed and not included in this
specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 637 668 B1

Description

BACKGROUND OF THE INVENTION

[0001] Ileal bile acid transporter (IBAT) is the main mechanism for re-absorption of bile acids from the GI tract. Partial or full blockade of that mechanism will result in lower concentration of bile acids in the small bowel wall, portal vein, liver parenchyma, intrahepatic biliary tree, extrahepatic biliary tree, including gall bladder.

[0002] Diseases which may benefit from partial or full blockade of the IBAT mechanism may be those either having as a primary pathophysiological defect, causing or having symptoms of too high concentration of bile acids in serum and in the above organs. WO 2008/058630 describes the effect of certain ileal bile acid transport (IBAT) in the treatment of liver disease related to fat disorders.

[0003] WO 2004/089350 discloses the use of IBAT inhibitors in the treatment of constipation.

[0004] EP 1535913 discloses the use of 1,4-benzothiazepine derivatives as IBAT inhibitors in the treatment of hyperlipidemia, cholestasis-caused hepatopathy, obesity, fatty liver and steatohepatitis.


[0005] WO 03/106482 and WO 03/022286 disclose certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as IBAT inhibitors, which are useful in the treatment of hyperlipidemia.

SUMMARY OF THE INVENTION

[0006] The present invention regards specific IBAT inhibitors as defined in the appended claims for use in the prophylaxis and/or treatment of a liver disease selected from the group consisting of Alagilles syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and pruritus of cholestatic liver disease.

DETAILED DESCRIPTION OF THE INVENTION

[0007] The present invention is defined in the appended claim. Disclosed herein are IBAT inhibitory compounds of formula (I):



wherein:

M is CH₂, NH


One of **R**¹ and **R**² are selected from hydrogen or C₁₋₆alkyl and the other is selected from C₁₋₆alkyl;

R^x and **R**^y are independently selected from hydrogen, hydroxy, amino, mercapto, C₁₋₆alkyl, C₁₋₆alkoxy, N-(C₁₋₆alkyl)amino, N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkylS(O)_a wherein a is 0 to 2

R^z is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, N-(C₁₋₆alkyl)amino, N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, N-(C₁₋₆alkyl)carbamoyl, N,N-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, N-(C₁₋₆alkyl)sulphamoyl and N,N-(C₁₋₆alkyl)₂sulphamoyl;

v is 0-5;

one of **R**⁴ and **R**⁵ is a group of formula (IA):



(IA)

R³ and **R⁶** and the other of **R⁴** and **R⁵** are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphonamoyl, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, N-(C₁₋₄alkyl)carbamoyl, N,N-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, N-(C₁₋₄alkyl)sulphonamoyl and N,N-(C₁₋₄alkyl)₂sulphonamoyl; wherein **R³** and **R⁶** and the other of **R⁴** and **R⁵** may be optionally substituted on carbon by one or more **R¹⁶**;

X is -O-, -N(R^a)-, -S(O)_b- or -CH(R^a)-; wherein R^a is hydrogen or C₁₋₆alkyl and b is 0-2;

Ring A is aryl or heteroaryl; wherein Ring A is optionally substituted by one or more substituents selected from **R¹⁷**;


R⁷ is hydrogen, C₁₋₄alkyl, carbocyclyl or heterocyclyl; wherein **R⁷** is optionally substituted by one or more substituents selected from **R¹⁸**;

R⁸ is hydrogen or C₁₋₄alkyl;


R⁹ is hydrogen or C₁₋₄alkyl;

R¹⁰ is hydrogen, C₁₋₄alkyl, carbocyclyl or heterocyclyl; wherein **R¹⁰** is optionally substituted by one or more substituents selected from **R¹⁹**;

R¹¹ is carboxy, sulfo, sulphinio, phosphono, -P(O)(OR^c)(OR^d), -P(O)(OH)(OR^c), -P(O)(OH)(R^d) or -P(O)(OR^c)(R^d) wherein R^c and R^d are independently selected from C₁₋₆alkyl; or **R¹¹** is a group of formula (IB) or (IC):



(IB)



(IC)

wherein:

Y is -N(Rⁿ)-, -N(Rⁿ)C(O)-, -N(Rⁿ)C(O)(CR^sR^t)_vN(Rⁿ)C(O)-, -O-, and -S(O)_a-; wherein a is 0-2, v is 1-2, R^s and R^t are independently selected from hydrogen or C₁₋₄alkyl optionally substituted by **R²⁶** and Rⁿ is hydrogen or C₁₋₄alkyl;

R¹² is hydrogen or C₁₋₄alkyl;

R¹³ and **R¹⁴** are independently selected from hydrogen, C₁₋₄alkyl, carbocyclyl or heterocyclyl; and when q is 0, **R¹⁴** may additionally be selected from hydroxy wherein **R¹³** and **R¹⁴** may be independently optionally substituted by one or more substituents selected from **R²⁰**;

R¹⁵ is carboxy, sulfo, sulphinio, phosphono, -P(O)(OR^e)(OR^f), -P(O)(OH)(OR^e), -P(O)(OH)(R^e) or -P(O)(OR^e)(R^f) wherein R^e and R^f are independently selected from C₁₋₆alkyl;

p is 1-3; wherein the values of **R¹³** may be the same or different;

q is 0-1;

r is 0-3; wherein the values of **R¹⁴** may be the same or different;

m is 0-2; wherein the values of **R¹⁰** may be the same or different;

n is 1-3; wherein the values of **R⁷** may be the same or different;

Ring B is a nitrogen linked heterocyclyl substituted on carbon by one group selected from **R²³**, and optionally additionally substituted on carbon by one or more **R²⁴**; and wherein if said nitrogen linked heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by a group selected from **R²⁵**;

R¹⁶, **R¹⁷** and **R¹⁸** are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphonamoyl, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, N-(C₁₋₄alkyl)amino,

N,N -(C_{1-4} alkyl) $_2$ amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl) $_2$ carbamoyl, C_{1-4} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl and N,N -(C_{1-4} alkyl) $_2$ sulphamoyl; wherein R^{16} , R^{17} and R^{18} may be independently optionally substituted on carbon by one or more R^{21} ;

R^{19} , R^{20} , R^{24} and R^{26} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl) $_2$ amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl) $_2$ carbamoyl, C_{1-4} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl) $_2$ sulphamoyl, carbocyclyl, heterocyclyl, benzyloxycarbonylamino, sulpho, sulphino, amidino, phosphono, -P(O)(OR^a)(OR^b), -P(O)(OH)(OR^a), -P(O)(OH)(R^a) or -P(O)(OR^a)(R^b), wherein R^a and R^b are independently selected from C_{1-6} alkyl; wherein R^{19} , R^{20} , R^{24} and R^{26} may be independently optionally substituted on carbon by one or more R^{22} ;

R^{21} and R^{22} are independently selected from halo, hydroxy, cyano, carbamoyl, ureido, amino, nitro, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, methyl, ethyl, methoxy, ethoxy, vinyl, allyl, ethynyl, methoxycarbonyl, formyl, acetyl, formamido, acetylamino, acetoxymethyl, methylamino, dimethylamino, N -methylcarbamoyl, N,N -dimethylcarbamoyl, methylthio, methylsulphonyl, mesyl, N -methylsulphamoyl and N,N -dimethylsulphamoyl;

R^{23} is carboxy, sulpho, sulphino, phosphono, -P(O)(OR^g)(OR^h), -P(O)(OH)(OR^g), -P(O)(OH)(R^g) or -P(O)(OR^g)(R^h) wherein R^g and R^h are independently selected from C_{1-6} alkyl;

R^{25} is selected from C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl) $_2$ carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

or a pharmaceutically acceptable salt thereof for use in the prophylaxis or treatment of a liver disease.

[0008] Compounds as used in accordance with the invention improve liver tests (serum amino transferases) and liver histology and significantly reduce hydroxyproline content and the number of infiltrating neutrophils and proliferating hepatocytes and cholangiocytes.

[0009] In the literature IBAT inhibitors are often referred to by different names. It is to be understood that where IBAT inhibitors are referred to herein, this term also encompasses compounds known in the literature as: i) ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitors; ii) bile acid transporter (BAT) inhibitors; iii) ileal sodium/bile acid cotransporter system inhibitors; iv) apical sodium-bile acid cotransporter inhibitors; v) ileal sodium-dependent bile acid transport inhibitors; vi) bile acid reabsorption (BARI's) inhibitors; and vii) sodium bile acid transporter (SBAT) inhibitors; where they act by inhibition of IBAT.

[0010] In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, " C_{1-6} alkyl" includes C_{1-4} alkyl, C_{1-3} alkyl, propyl, isopropyl and t -butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only. A similar convention applies to other radicals, for example "phenyl C_{1-6} alkyl" would include phenyl C_{1-4} alkyl, benzyl, 1-phenylethyl and 2-phenylethyl. The term "halo" refers to fluoro, chloro, bromo and iodo.

[0011] Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

[0012] "Heteroaryl" is a totally unsaturated, mono or bicyclic ring containing 3 - 12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. Preferably "heteroaryl" refers to a totally unsaturated, monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. In another aspect, "heteroaryl" refers to a totally unsaturated, monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 8, 9 or 10 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. Examples and suitable values of the term "heteroaryl" are thienyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, triazolyl, pyranlyl, indolyl, pyrimidyl, pyrazinyl, pyridazinyl, pyridyl and quinolyl. Preferably the term "heteroaryl" refers to thienyl or indolyl.

[0013] "Aryl" is a totally unsaturated, mono or bicyclic carbon ring that contains 3 - 12 atoms. Preferably "aryl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "aryl" include phenyl or naphthyl. Particularly "aryl" is phenyl.

[0014] A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3 - 12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂- group can optionally be replaced by a -C(O)- or a ring sulphur atom may be optionally oxidised to form the S-oxides. Preferably a "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂-group can optionally be replaced by a -C(O)-

or a ring sulphur atom may be optionally oxidised to form S-oxide(s). Examples and suitable values of the term "heterocyclyl" are thiazolidinyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidinonyl, 2,5-dioxopyrrolidinyl, 2-benzoxazolinonyl, 1,1-dioxotetrahydrothienyl, 2,4-dioxoimidazolidinyl, 2-oxo-1,3,4-(4-triazolinyl), 2-oxazolidinonyl, 5,6-dihydrouracilyl, 1,3-benzodioxolyl, 1,2,4-oxadiazolyl, 2-azabicyclo [2.2.1] heptyl, 4-thiazolidonyl, morpholino, 2-oxotetrahydrofuranyl, tetrahydrofuranyl, 2,3-dihydrobenzofuranyl, benzothienyl, tetrahydropyranyl, piperidyl, 1-oxo-1,3-dihydroisoindolyl, piperazinyl, thiomorpholino, 1,1-dioxothiomorpholino, tetrahydropyranyl, 1,3-dioxolanyl, homopiperazinyl, thienyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, 1,2,4-triazolyl, 1,3,4-triazolyl, pyranlyl, indolyl, pyrimidyl, thiazolyl, pyrazinyl, pyridazinyl, pyridyl, 4-pyridonyl, quinolyl and 1-isoquinolonyl.

[0015] A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3 - 12 atoms; wherein a -CH₂- group can optionally be replaced by a -C(O)-. Preferably "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl. Particularly "carbocyclyl" is cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl or 1-oxoindanyl.

[0016] An example of "C₁₋₆alkanoyloxy" and "C₁₋₄alkanoyloxy" is acetoxy. Examples of "C₁₋₆alkoxycarbonyl" and "C₁₋₄alkoxycarbonyl" include methoxycarbonyl, ethoxycarbonyl, *n*- and *t*-butoxycarbonyl. Examples of "C₁₋₆alkoxy" and "C₁₋₄alkoxy" include methoxy, ethoxy and propoxy. Examples of "C₁₋₆alkanoylamino" and "C₁₋₄alkanoylamino" include formamido, acetamido and propionylamino. Examples of "C₁₋₆alkylS(O)_a" wherein a is 0 to 2" and "C₁₋₄alkylS(O)_a" wherein a is 0 to 2" include methylthio, ethylthio, methylsulphanyl, ethylsulphanyl, mesyl and ethylsulphonyl. Examples of "C₁₋₆alkanoyl" and "C₁₋₄alkanoyl" include C₁₋₃alkanoyl, propionyl and acetyl. Examples of "*N*-(C₁₋₆alkyl)amino" and "*N*-(C₁₋₄alkyl)amino" include methylamino and ethylamino. Examples of "*N,N*-(C₁₋₆alkyl)₂amino" and "*N,N*-(C₁₋₄alkyl)₂amino" include di-*N*-methylamino, di-(*N*-ethyl)amino and *N*-ethyl-*N*-methylamino. Examples of "C₂₋₆alkenyl" and "C₂₋₄alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C₂₋₆alkynyl" and "C₂₋₄alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of "*N*-(C₁₋₆alkyl)sulphamoyl" and "*N*-(C₁₋₄alkyl)sulphamoyl" are *N*-(C₁₋₃alkyl)sulphamoyl, *N*-(methyl)sulphamoyl and *N*-(ethyl)sulphamoyl. Examples of "*N*-(C₁₋₆alkyl)₂sulphamoyl" and "*N*-4alkyl)₂sulphamoyl" are *N,N*-(dimethyl)sulphamoyl and *N*-(methyl)-*N*-(ethyl)sulphamoyl. Examples of "*N*-(C₁₋₆alkyl)carbamoyl" and "*N*-(C₁₋₄alkyl)carbamoyl" are methylaminocarbonyl and ethylaminocarbonyl. Examples of "*N,N*-(C₁₋₆alkyl)₂carbamoyl" and "*N,N*-(C₁₋₄alkyl)₂carbamoyl" are dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "C₁₋₆alkoxycarbonylamino" are ethoxycarbonylamino and *t*-butoxycarbonylamino. Examples of "*N*-(C₁₋₆alkyl)ureido" are *N*-methylureido and *N*-ethylureido. Examples of "*N*-(C₁₋₆alkyl)ureido" are *N*-methylureido and *N*-ethylureido. Examples of "*N,N*-(C₁₋₆alkyl)₂ureido" are *N,N*-dimethylureido and *N*-methyl-*N*-ethylureido. Examples of "*N*-(C₁₋₆alkyl)-*N*-(C₁₋₆alkyl)ureido" are *N*-methyl-*N*-methylureido and *N*-propyl-*N*-methylureido. Examples of "*N,N*-(C₁₋₆alkyl)₂-*N*-(C₁₋₆alkyl)ureido" are *N,N*-dimethyl-*N*-methylureido and *N*-methyl-*N*-ethyl-*N*-propylureido.

[0017] A suitable pharmaceutically acceptable salt of a compound is, for example, an acid-addition salt of a compound which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.

[0018] In addition a suitable pharmaceutically acceptable salt of a compound which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl) amine.

[0019] It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that formula (I) encompasses all such solvated forms which possess IBAT inhibitory activity.

[0020] Preferred values of **R¹**, **R²**, **R³**, **R⁴**, **R⁵** and **R⁶** are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

[0021] Preferably **R¹** and **R²** are independently selected from C₁₋₄alkyl.

More preferably **R¹** and **R²** are independently selected from ethyl or butyl.

[0022] More preferably **R¹** and **R²** are independently selected from ethyl, propyl or butyl.

In one aspect particularly **R¹** and **R²** are both butyl.

In a further aspect particularly **R¹** and **R²** are both propyl.

In another aspect particularly one of **R¹** and **R²** is ethyl and the other is butyl.

[0023] Preferably **R^x** and **R^y** are independently selected from hydrogen or C₁₋₆alkyl.

More preferably **R^x** and **R^y** are both hydrogen.

Preferably **R^z** is selected from halo, amino, C₁₋₆alkyl, C₁₋₆alkoxycarbonylamino or *N*-(C₁₋₆alkyl)ureido.

[0024] More preferably **R^z** is selected from chloro, amino, *t*-butyl, *t*-butoxycarbonylamino or *N*-(*t*-butyl)ureido.

[0025] Preferably **v** is 0 or 1.

In one aspect, more preferably **v** is 0.

In one aspect, more preferably **v** is 1.

In one aspect preferably **R**⁴ is a group of formula **(IA)** (as depicted above).

In another aspect preferably **R**⁵ is a group of formula **(IA)** (as depicted above).

[0026] Preferably **R**³ and **R**⁶ are hydrogen.

Preferably the other of **R**⁴ and **R**⁵ that is not the group of formula **(IA)** is selected from halo, C₁₋₄alkoxy or C₁₋₄alkylS(O)_a wherein a is 0 to 2; wherein that **R**⁴ or **R**⁵ may be optionally substituted on carbon by one or more **R**¹⁶; wherein **R**¹⁶ is independently selected from hydroxy and *N,N*-(C₁₋₄alkyl)₂amino.

[0027] More preferably the other of **R**⁴ and **R**⁵ that is not the group of formula **(IA)** is selected from bromo, methoxy, isopropoxy, methylthio, ethylthio, isopropylthio or mesyl; wherein that **R**⁴ or **R**⁵ may be optionally substituted on carbon by one or more **R**¹⁶; wherein **R**¹⁶ is independently selected from hydroxy and *N,N*-dimethylamino.

[0028] Particularly the other of **R**⁴ and **R**⁵ that is not the group of formula **(IA)** is selected from bromo, methoxy, isopropoxy, methylthio, ethylthio, isopropylthio, 2-hydroxyethylthio, 2-(*N,N*-dimethylamino) ethylthio or mesyl.

[0029] More particularly the other of **R**⁴ and **R**⁵ that is not the group of formula **(IA)** is methylthio. Preferably the other of **R**⁴ and **R**⁵ that is not the group of formula **(IA)** is selected from hydrogen, halo, C₁₋₄alkoxy or C₁₋₄alkylS(O)_a wherein a is 0 to 2; wherein that **R**⁴ or **R**⁵ may be optionally substituted on carbon by one or more **R**¹⁶; wherein **R**¹⁶ is independently selected from hydroxy, carboxy and *N,N*-(C₁₋₄alkyl)₂amino.

[0030] More preferably the other of **R**⁴ and **R**⁵ that is not the group of formula **(IA)** is selected from hydrogen, bromo, methoxy, isopropoxy, methylthio, ethylthio, isopropylthio or mesyl; wherein that **R**⁴ or **R**⁵ may be optionally substituted on carbon by one or more **R**¹⁶; wherein **R**¹⁶ is independently selected from hydroxy, carboxy and *N,N*-dimethylamino.

[0031] Particularly the other of **R**⁴ and **R**⁵ that is not the group of formula **(IA)** is selected from hydrogen, bromo, methoxy, isopropoxy, methylthio, carboxymethylthio, ethylthio, isopropylthio, 2-hydroxyethylthio, 2-(*N,N*-dimethylamino) ethylthio or mesyl.

In another aspect, more preferably the other of **R**⁴ and **R**⁵ that is not the group of formula **(IA)** is selected from hydrogen, chloro, bromo, methoxy, isopropoxy, methylthio, ethylthio or isopropylthio; wherein that **R**⁴ or **R**⁵ may be optionally substituted on carbon by one or more **R**¹⁶; wherein **R**¹⁶ is independently selected from hydroxy, carboxy and *N,N*-dimethylamino.

[0032] In another aspect, particularly the other of **R**⁴ and **R**⁵ that is not the group of formula **(IA)** is selected from hydrogen, chloro, bromo, methoxy, isopropoxy, methylthio, carboxymethylthio, ethylthio, isopropylthio, 2-hydroxyethylthio or 2-(*N,N*-dimethylamino) ethylthio.

[0033] In another aspect, more particularly the other of **R**⁴ and **R**⁵ that is not the group of formula **(IA)** is bromo or chloro.

In another aspect, more particularly the other of **R**⁴ and **R**⁵ that is not the group of formula **(IA)** is methoxy.

[0034] In one aspect, preferably **Ring A** is aryl.

In another aspect, preferably **Ring A** is heteroaryl.

When **Ring A** is aryl, preferably **Ring A** is phenyl.

When **Ring A** is heteroaryl, preferably **Ring A** is thienyl or indolyl.

Preferably **Ring A** is aryl or heteroaryl; wherein **Ring A** is optionally substituted by one or more substituents selected from **R**¹⁷; wherein **R**¹⁷ is selected from halo, hydroxy or Cl 4alkyl; wherein **R**¹⁷ may be optionally substituted on carbon by one or more **R**²¹; wherein **R**²¹ is selected from halo.

Preferably **X** is-O.

[0035] More preferably **Ring A** is phenyl, thienyl or indolyl; wherein **Ring A** is optionally substituted by one or more substituents selected from halo, hydroxy or trifluoromethyl.

[0036] Particularly **Ring A** is selected from phenyl, 4-hydroxyphenyl, thien-2-yl, 4-trifluoromethylphenyl, 3-hydroxyphenyl, 2-fluorophenyl, 2,3-dihydroxyphenyl or indol-3-yl.

More particularly **Ring A** is phenyl.

[0037] In another aspect, preferably **Ring A** is aryl or heteroaryl; wherein **Ring A** is optionally substituted by one or more substituents selected from **R**¹⁷; wherein **R**¹⁷ is selected from halo, hydroxy, C₁₋₄alkyl or C₁₋₄alkoxy; wherein **R**¹⁷ may be optionally substituted on carbon by one or more **R**²¹; wherein **R**²¹ is selected from halo.

[0038] In another aspect, more preferably **Ring A** is phenyl, thienyl or indolyl; wherein **Ring A** is optionally substituted by one or more substituents selected from halo, hydroxy, methoxy or trifluoromethyl.

[0039] In another aspect, particularly **Ring A** is selected from phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, thien-2-yl, 4-trifluoromethylphenyl, 3-hydroxyphenyl, 2-fluorophenyl, 2,3-dihydroxyphenyl or indol-3-yl.

In a further aspect, particularly **Ring A** is selected from phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, thien-2-yl, 4-trifluoromethylphenyl, 3-hydroxyphenyl, 2-fluorophenyl, 4-fluorophenyl, 2,3-dihydroxyphenyl or indol-3-yl.

[0040] Preferably **R**⁷ is hydrogen, C₁₋₄alkyl or carbocyclyl.

More preferably **R**⁷ is hydrogen, methyl or phenyl.

Particularly **R**⁷ is hydrogen.

In one aspect, preferably **R**⁸ is hydrogen.

In another aspect, preferably **R**⁸ is C₁₋₄alkyl.

In another aspect, more preferably **R**⁸ is hydrogen or methyl.

In one aspect, preferably R^9 is hydrogen.

In another aspect, preferably R^9 is C_{1-4} alkyl.

In another aspect, more preferably R^9 is hydrogen or methyl.

Preferably R^{10} is hydrogen.

- 5 In one aspect, preferably R^{11} is carboxy, sulpho, sulphino, phosphono, $-P(O)(OR^c)(OR^d)$, $-P(O)(OH)(OR^c)$, $-P(O)(OH)(R^d)$ or $-P(O)(OR^c)(R^d)$ wherein R^c and R^d are independently selected from C_{1-6} alkyl.

[0041] In another aspect, preferably R^{11} is a group of formula (IB) (as depicted above).

[0042] Preferably R^{11} is carboxy, $-P(O)(OH)(OR^c)$ or a group of formula (IB) (as depicted above).

[0043] More preferably R^{11} is carboxy, $-P(O)(OH)(OEt)$ or a group of formula (IB) (as depicted above).

- 10 [0044] In another aspect, preferably R^{11} is carboxy, sulpho, $-P(O)(OH)(OR^c)$ wherein R^c is selected from C_{1-4} alkyl or a group of formula (IB) (as depicted above).

Preferably Y is $-NH-$ or $-NHC(O)-$.

More preferably Y is $-NHC(O)-$.

In one aspect, preferably R^{12} is hydrogen.

- 15 In another aspect, preferably R^{12} is C_{1-4} alkyl.

In another aspect, more preferably R^{12} is hydrogen or methyl.

Preferably R^{13} is hydrogen, C_{1-4} alkyl or carbocyclyl; wherein R^{13} is optionally substituted by one or more substituents selected from R^{20} ; wherein R^{20} is hydroxy.

More preferably R^{13} is hydrogen, methyl or phenyl; wherein R^{13} is optionally substituted by one or more substituents selected from R^{20} ; wherein R^{20} is hydroxy.

- 20 Particularly R^{13} is hydrogen, hydroxymethyl or phenyl.

More particularly R^{13} is hydrogen or hydroxymethyl.

[0045] In another aspect, preferably R^{13} is hydrogen, C_{1-4} alkyl or carbocyclyl; wherein R^{13} is optionally substituted by one or more substituents selected from R^{20} ; wherein R^{20} is hydroxy, carboxy, carbocyclyl or amino; wherein R^{20} may be optionally substituted on carbon by one or more R^{22} ; R^{22} is hydroxy.

- 25 [0046] In another aspect, more preferably R^{13} is hydrogen, methyl, ethyl, butyl or phenyl; wherein R^{13} is optionally substituted by one or more substituents selected from R^{20} ; wherein R^{20} is hydroxy, carboxy, phenyl or amino; wherein R^{20} may be optionally substituted on carbon by one or more R^{22} ; R^{22} is hydroxy.

[0047] In another aspect, particularly R^{13} is hydrogen, hydroxymethyl, 4-aminobutyl, 2-carboxyethyl, 4-hydroxybenzyl or phenyl.

- 30 [0048] In a further aspect, preferably R^{13} is hydrogen, C_{1-4} alkyl or carbocyclyl; wherein R^{13} is optionally substituted by one or more substituents selected from R^{20} ; wherein R^{20} is hydroxy, carboxy, carbocyclyl, heterocyclyl or amino; wherein R^{20} may be optionally substituted on carbon by one or more R^{22} ; R^{22} is hydroxy.

[0049] In a further aspect, more preferably R^{13} is hydrogen, methyl, ethyl, butyl or phenyl; wherein R^{13} is optionally substituted by one or more substituents selected from R^{20} ; wherein R^{20} is hydroxy, carboxy, phenyl, imidazolyl or amino; wherein R^{20} may be optionally substituted on carbon by one or more R^{22} ; R^{22} is hydroxy.

- 35 [0050] In a further aspect, particularly R^{13} is hydrogen, hydroxymethyl, 4-aminobutyl, 2-carboxyethyl, 4-hydroxybenzyl, imidazol-5-ylmethyl or phenyl.

[0051] In another further aspect, preferably R^{13} is hydrogen, C_{1-4} alkyl, carbocyclyl or R^{23} ; wherein R^{13} is optionally substituted by one or more substituents selected from R^{20} ; wherein R^{20} is hydroxy, C_{1-4} alkylS(O)_a wherein a is 0, C_{1-4} alkoxy, amino, carbocyclyl, heterocyclyl or mercapto; wherein R^{20} may be independently optionally substituted on carbon by one or more R^{22} ; R^{22} is selected from hydroxy; and R^{23} is carboxy.

[0052] In another further aspect, more preferably R^{13} is hydrogen, methyl, ethyl, butyl or phenyl or R^{23} ; wherein R^{13} is optionally substituted by one or more substituents selected from R^{20} ; wherein R^{20} is hydroxy, methylthio, methoxy, amino, imidazolyl or mercapto; wherein R^{20} may be independently optionally substituted on carbon by one or more R^{22} ; R^{22} is selected from hydroxy; and R^{23} is carboxy.

- 45 [0053] In another further aspect, particularly R^{13} is hydrogen, carboxy, hydroxymethyl, mercaptomethyl, methoxymethyl, methylthiomethyl, 2-methylthioethyl, 4-aminobutyl, 4-hydroxybenzyl, imidazol-5-ylmethyl or phenyl.

[0054] In another aspect more particularly R^{13} is methylthiomethyl, methylsulphonylmethyl or methylsulphonylmethyl.

- 50 [0055] Preferably R^{14} is hydrogen.

[0056] In another aspect, preferably R^{14} is selected from hydrogen, C_{1-4} alkyl or carbocyclyl; wherein said C_{1-4} alkyl or carbocyclyl may be optionally substituted by one or more substituents selected from R^{20} ; and R^{20} is hydroxy.

In another aspect, more preferably R^{14} is selected from hydrogen, methyl or phenyl; wherein said methyl or phenyl may be optionally substituted by one or more substituents selected from R^{20} ; and R^{20} is hydroxy.

- 55 [0057] In another aspect, particularly R^{14} is hydrogen, phenyl or hydroxymethyl.

Particularly R^{15} is carboxy or sulpho.

[0058] In one aspect, more particularly R^{15} is carboxy.

In another aspect, more particularly R^{15} is sulpho.

[0059] Preferably **R¹⁵** is carboxy, sulpho, -P(O)(OR^e)(OR^f), -P(O)(OH)(OR^e), -P(O)(OH)(R^e) or -P(O)(OR^e)(R^f) wherein R^e and R^f are independently selected from C₁₋₄alkyl.

More preferably **R¹⁵** is carboxy, sulpho, -P(O)(OR^e)(OR^f), -P(O)(OH)(OR^e), -P(O)(OH)(R^e) or -P(O)(OR^e)(R^f) wherein R^e and R^f are independently selected from methyl or ethyl.

Preferably **R¹⁵** is carboxy, sulpho, -P(O)(OEt)(OEt), -P(O)(OH)(OEt), -P(O)(OH)(Me) or -P(O)(OEt)(Me).

[0060] Preferably **R¹⁵** is carboxy, sulpho, phosphono, -P(O)(OR^e)(OR^f), -P(O)(OH)(OR^e), -P(O)(OH)(R^e) or -P(O)(OR^e)(R^f) wherein R^e and R^f are independently selected from C₁₋₄alkyl or **R¹⁵** is a group of formula **(IC)** (as depicted above).

More preferably **R¹⁵** is carboxy, sulpho, phosphono, -P(O)(OR^e)(OR^f), -P(O)(OH)(OR^e), -P(O)(OH)(R^e) or -P(O)(OR^e)(R^f) wherein R^e and R^f are independently selected from methyl or ethyl or **R¹⁵** is a group of formula **(IC)** (as depicted above).

Preferably **R¹⁵** is carboxy, sulpho, phosphono, -P(O)(OEt)(OEt), -P(O)(OH)(OEt), -P(O)(OH)(Me) or -P(O)(OEt)(Me) or **R¹⁵** is a group of formula **(IC)** (as depicted above).

[0063] In one aspect, preferably **R¹⁵** is carboxy.

In another aspect, preferably **R¹⁵** is sulpho.

In another aspect, preferably **R¹⁵** is -P(O)(OH)(OEt).

In another aspect, preferably **R¹⁵** is -P(O)(OH)(Me).

In another aspect, preferably **R¹⁵** is -P(O)(OEt)(Me).

In one aspect, preferably **R²⁴** is hydrogen.

In another aspect, preferably **R²⁴** is C₁₋₄alkyl.

[0064] Preferably **R²⁵** is hydrogen.

Preferably **R²⁶** is carboxy.

[0065] Preferably **p** is 1 or 2; wherein the values of **R¹³** may be the same or different.

In one aspect, more preferably **p** is 1.

In another aspect, more preferably **p** is 2; wherein the values of **R¹³** may be the same or different.

[0066] In a further aspect, more preferably **p** is 3; wherein the values of **R¹³** may be the same or different.

In one aspect, preferably **q** is 0. In a further aspect, preferably **q** is 1.

In one aspect, preferably **r** is 0.

In one aspect, more preferably **r** is 1.

In another aspect, more preferably **r** is 2; wherein the values of **R¹⁴** may be the same or different.

In a further aspect, more preferably **r** is 3; wherein the values of **R¹⁴** may be the same or different.

Preferably **m** is 0.

In another aspect, preferably **m** is 0 or 1.

Preferably **n** is 1.

In another aspect, preferably **n** is 1 or 2.

Preferably **z** is 1.

The group of formula **(IA)** wherein **R⁷** is hydrogen, methyl or phenyl, **n** is 1, **Ring A** is phenyl, thienyl or indolyl; wherein **Ring A** is optionally substituted by one or more substituents selected from halo, hydroxy or trifluoromethyl, **m** is 0 and **R⁹** is carboxy, -P(O)(OH)(OR^c) or a group of formula **(IB)**.

The group of formula **(IA)** wherein: X is -O-.

Ring A is phenyl, thienyl or indolyl; wherein **Ring A** is optionally substituted by one or more substituents selected from halo, hydroxy, methoxy or trifluoromethyl;

R⁷ is hydrogen, methyl or phenyl;

R⁸ is hydrogen or methyl;

R⁹ is hydrogen or methyl;

R¹⁰ is hydrogen;

m is 0-2 wherein the values of **R¹⁰** may be the same or different; and **R¹¹** is carboxy, -P(O)(OH)(OEt) or a group of formula **(IB)** (as depicted in claim 1); The group of formula **(IB)** wherein **R¹⁰** is hydrogen, hydroxymethyl or phenyl, **p** is 1 or 2; wherein the values of **R¹⁰** may be the same or different and **R¹¹** is carboxy or sulpho.

The group of formula **(IB)** wherein:

R¹² is hydrogen or methyl;

R¹³ is hydrogen, methyl, ethyl, butyl or phenyl or **R²³**; wherein **R¹³** is optionally substituted by one or more substituents selected from **R²⁰**; **R²⁰** is hydroxy, methylthio, methoxy, amino, imidazolyl or mercapto; wherein **R²⁰** may be independently optionally substituted on carbon by one or more hydroxy; **R²³** is carboxy; **Y** is -NH- or -NHC(O)-; **R¹⁴** is selected from hydrogen, methyl or phenyl; wherein said methyl or phenyl may be optionally substituted by one or more substituents selected from hydroxy; **R¹⁵** is carboxy, sulpho, phosphono, -P(O)(OR^e)(OR^f), -P(O)(OH)(OR^e),

-P(O)(OH)(R^e) or -P(O)(OR^e)(R^f) wherein R^e and R^f are independently selected from methyl or ethyl or R¹⁵ is a group of formula (IC) (as depicted in claim 1);

p is 1-3 wherein the values of R¹³ may be the same or different;

q is 0-1; and

r is 0-3 wherein the values of R¹⁴ may be the same or different;

The group of formula (IC) wherein

R²⁴ is hydrogen;

R²⁵ is hydrogen;

R²⁶ is carboxy; and

z is 1; or a pharmaceutically acceptable salt thereof.

[0067] Also disclosed herein is a compound of formula (I) as depicted above wherein:

R¹ and R² are independently selected from ethyl or butyl;

R³ and R⁶ are hydrogen;

R⁴ is selected from halo, C₁₋₄alkoxy or C₁₋₄alkylS(O)_a wherein a is 0 to 2; wherein that R⁴ may be optionally substituted on carbon by one or more R¹⁶; wherein R¹⁶ is independently selected from hydroxy and N,N-(C₁₋₄-alkyl)₂amino;

R⁵ is a group of formula (IA);

Ring A is aryl or heteroaryl; wherein Ring A is optionally substituted by one or more substituents selected from R¹⁷; wherein

R¹⁷ is selected from halo, hydroxy or C₁₋₄alkyl; wherein R¹⁷ may be optionally substituted on carbon by one or more R²¹; wherein

R²¹ is selected from halo;

R⁷ is hydrogen, C₁₋₄alkyl or carbocyclyl;

R¹¹ is carboxy, -P(O)(OH)(OR^c) or a group of formula (IB) (as depicted above);

R¹³ is hydrogen, C₁₋₄alkyl or carbocyclyl; wherein R¹³ is optionally substituted by one or more substituents selected from R²⁰; wherein

R²⁰ is hydroxy;

R¹⁵ is carboxy or sulpho;

p is 1 or 2; wherein the values of R¹³ may be the same or different;

m is 0; and

n is 1;

or a pharmaceutically acceptable salt thereof.

[0068] Also disclosed herein is a compound of formula (I) as depicted above wherein:

R¹ and R² are both butyl or one of R¹ and R² is ethyl and the other is butyl;

R⁴ is methylthio;

R⁵ is a group of formula (IA) (as depicted above);

R³ and R⁶ are hydrogen;

Ring A is phenyl;

R⁷ is hydrogen;

R¹¹ is a group of formula (IB) (as depicted above);

R¹³ is hydrogen or hydroxymethyl;

R¹⁵ is carboxy or sulpho;

p is 1 or 2; wherein the values of R¹³ may be the same or different;

m is 0;

n is 1;

or a pharmaceutically acceptable salt thereof.

[0069] Also disclosed herein is a compound of formula (I) as depicted above wherein:

R¹ and R² are independently selected from ethyl or butyl;

R³ and R⁶ are hydrogen;

R⁴ is selected from halo, C₁₋₄alkoxy or C₁₋₄alkylS(O)_a wherein a is 0 to 2; wherein that R⁴ may be optionally substituted on carbon by one or more R¹⁶; wherein R¹⁶ is independently selected from hydroxy and N,N-(C₁₋₄-alkyl)₂amino;

R⁵ is a group of formula (IA);

Ring A is aryl or heteroaryl; wherein Ring A is optionally substituted by one or more substituents selected from R¹⁷;

R⁷ is hydrogen, C₁₋₄alkyl or carbocyclyl;

R⁸ is hydrogen or methyl;

R⁹ is hydrogen or methyl;

R¹¹ is carboxy, -P(O)(OH)(OR^c) or a group of formula **(IB)** (as depicted above);

X is -NH- or -NHC(O)-;

R¹² is hydrogen or methyl;

R¹³ is hydrogen, C₁₋₄alkyl or carbocyclyl; wherein **R**¹³ is optionally substituted by one or more substituents selected from **R**²⁰;

R¹⁴ is hydrogen;

R¹⁵ is carboxy or sulphy;

R¹⁷ is selected from halo, hydroxy, C₁₋₄alkyl or C₁₋₄alkoxy; wherein **R**¹⁷ may be optionally substituted on carbon by one or more **R**²¹;

R²⁰ is hydroxy, carboxy, carbocyclyl or amino; wherein **R**²⁰ may be optionally substituted on carbon by one or more **R**²²;

R²¹ is selected from halo;

R²² is hydroxy;

p is 1-3; wherein the values of **R**¹³ may be the same or different.

q is 0-1;

r is 0-3; wherein the values of **R**¹⁴ may be the same or different; and wherein if **q** is 1, **r** is not 0;

m is 0-2; and

n is 1-3;

or a pharmaceutically acceptable salt thereof.

[0070] Also disclosed herein is a compound of formula **(I)** as depicted above wherein:

R¹ and **R**² are independently selected from C₁₋₄alkyl;

R^x and **R**^y are both hydrogen;

R^z is selected from halo, amino, C₁₋₆alkyl, C₁₋₆alkoxycarbonylamino or *N'*-(C₁₋₆alkyl)ureido; **v** is 0 or 1;

R³ and **R**⁶ are hydrogen;

one of **R**⁴ and **R**⁵ is a group of formula **(IA)** (as depicted above) and the other is selected from hydrogen, halo, C₁₋₄alkoxy or C₁₋₄alkylS(O)_a wherein **a** is 0 to 2; wherein that **R**⁴ or **R**⁵ may be optionally substituted on carbon by one or more **R**¹⁶; wherein **R**¹⁶ is independently selected from hydroxy, carboxy and *N,N*-(C₁₋₄alkyl)₂amino;

X is -O-;

R⁷ is hydrogen, methyl or phenyl;

R⁸ is hydrogen or methyl;

Ring A is aryl or heteroaryl; wherein **Ring A** is optionally substituted by one or more substituents selected from **R**¹⁷; wherein **R**¹⁷ is selected from halo, hydroxy, C₁₋₄alkyl or C₁₋₄alkoxy; wherein **R**¹⁷ may be optionally substituted on carbon by one or more **R**²¹; wherein

R²¹ is selected from halo;

R⁹ is hydrogen or methyl;

R¹⁰ is hydrogen;

R¹¹ is carboxy, -P(O)(OH)(OR^c) wherein **R**^c is selected from C₁₋₄alkyl or a group of formula **(IB)** (as depicted above);

R¹² is hydrogen or methyl;

Y is -NH- or -NHC(O)-;

R¹³ is hydrogen, C₁₋₄alkyl, carbocyclyl or **R**²³; wherein **R**¹³ is optionally substituted by one or more substituents selected from **R**²⁰; wherein **R**²⁰ is hydroxy, C₁₋₄alkylS(O)_a wherein **a** is 0, C₁₋₄alkoxy, amino, carbocyclyl, heterocyclyl or mercapto; wherein **R**²⁰ may be independently optionally substituted on carbon by one or more **R**²²; **R**²² is selected from hydroxy; and **R**²³ is carboxy;

R¹⁴ is selected from hydrogen, C₁₋₄alkyl or carbocyclyl; wherein said C₁₋₄alkyl or carbocyclyl may be optionally substituted by one or more substituents selected from **R**²⁰; and **R**²⁰ is hydroxy;

R¹⁵ is carboxy, sulphy, phosphono, -P(O)(OR^e)(OR^f), -P(O)(OH)(OR^e), -P(O)(OH)(R^e) or -P(O)(OR^e)(R^f) wherein **R**^e and **R**^f are independently selected from C₁₋₄alkyl or **R**¹⁵ is a group of formula **(IC)** (as depicted above);

R²⁴ is hydrogen;

R²⁵ is hydrogen;

R²⁶ is carboxy;

p is 1-3; wherein the values of **R**¹³ may be the same or different;

q is 0-1;

r is 0-3; wherein the values of **R**¹⁴ may be the same or different;

m is 0-2; wherein the values of **R¹⁰** may be the same or different;

n is 1-2; wherein the values of **R⁷** may be the same or different;


z is 0-1; wherein the values of **R²⁵** may be the same or different;

or a pharmaceutically acceptable salt thereof.

In another aspect, preferred compounds are any one of the Examples or a pharmaceutically acceptable salt thereof.

In another aspect, preferred compounds are any one of the Examples or a pharmaceutically acceptable salt thereof.

[0071] In a first aspect, the invention relates to a compound of formula II



Formula II

wherein

M is CH₂ or NH;

R¹ is H or hydroxy;

R² is H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃, or -CH₂CH₂SCH₃;

for use in the prophylaxis or treatment of a liver disease selected from the group consisting of Alagilles syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and pruritus of cholestatic liver disease.

[0072] Examples of useful substances in accordance with the invention are:

- 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N-(carboxymethyl)carbamoyl] benzyl) carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine,
- 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(S)-1-carboxyethyl) carbamoyl] benzyl) carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiadiazepine,
- 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N-((S)-1-carboxypropyl) carbamoyl]benzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine,
- 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N-((R)-1-carboxy-2-methylthioethyl)carbamoyl]benzyl) carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine,
- 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl) carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine,
- 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N-((R)-1-carboxy-2-methylthioethyl)carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine,
- 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine,
- 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine,
- 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N-((S)-1-carboxybutyl) carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine,
- 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N-((S)-1-carboxyethyl) carbamoyl]benzyl)carbamoyl-

methoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine,
 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)- α -[N'-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl}
 carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine,
 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)- α -[N'-((S)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}car-
 bamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine,
 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)- α -[N'-((S)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxy-
 benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine and
 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-1'-phenyl-1'-[N'-(carboxymethyl) carbamoyl]methyl}car-
 bamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine.

Compounds of formula (II) may have chiral centres and/or geometric isomeric centres (E-and Z-isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess IBAT inhibitory activity.

The invention relates to any and all tautomeric forms of the compounds of formula (II) that possess IBAT inhibitory activity.

The invention also relates to all possible isomers of the compounds of the invention such as, optical and/or geometrical, pure or as a mixture, in all proportions, of the said compounds of formula II and those specifically mentioned and the possible tautomeric forms

In certain embodiments, compounds described herein have one or more chiral centres. As such, all stereoisomers are envisioned herein. In various embodiments, compounds described herein are present in optically active or racemic forms. It is to be understood that the compounds of the present invention encompasses racemic, optically-active, regio-isomeric and stereoisomeric forms, or combinations thereof that possess the therapeutically useful properties described herein. Preparation of optically active forms is achieved in any suitable manner, including by way example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase. In some embodiments, mixtures of one or more isomer are utilized as the therapeutic compound described herein. In certain embodiments, compounds described herein, contains one or more chiral centres. These compounds are prepared by any means, including enantioselective synthesis and/or separation of a mixture of enantiomers and/or diastereomers. Resolution of compounds and isomers thereof is achieved by any means including, by way of example, chemical processes, enzymatic processes, fractional crystallization, distillation, chromatography, and the like.

[0073] The compounds may exist in free-acid or free-base form, or in a pharmaceutically acceptable salt form. In certain embodiments, a compound described herein exists in an unsolvated or solvated form, wherein solvated forms comprise any pharmaceutically acceptable solvent, e.g., water, ethanol, and the like.

[0074] The invention further regards a composition comprising at least one IBAT inhibitor of Formula (II), for use in the prophylaxis and/or treatment of a liver disease selected from the group consisting of Alagilles syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and pruritus of cholestatic liver disease.

[0075] An IBAT inhibitor of Formula II may be used together with at least one other therapeutically active compound as described herein, in the preparation of a medicament for the prophylactic and/or therapeutic treatment of a liver disease selected from the group consisting of Alagilles syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and pruritus of cholestatic liver disease.

Liver diseases

[0076] Liver disease is herein defined as any Bile Acid (BA) dependent disease in the liver and in organs connected therewith, such as the pancreas portal vein, the liver parenchyma, the intrahepatic biliary tree, the extrahepatic biliary tree, and the gall bladder.

Ileal bile acid transporter (IBAT) is the main mechanism for re-absorption of bile acids from the GI tract. Partial or full blockade of that mechanism will result in lower concentration of bile acids in the small bowel wall, the portal vein, the liver parenchyma, the intrahepatic biliary tree, the extrahepatic biliary tree, and in the gall bladder. Diseases which may benefit from partial or full blockade of the IBAT mechanism may be those having a primary pathophysiological defect, causing or having symptoms of too high concentration of bile acids in serum and in the above organs.

[0077] Examples of liver diseases as disclosed herein include liver parenchyma; an Inherited metabolic disorder of the liver; Byler syndrome; a primary defect of bile acid (BA) synthesis such as cerebrotendinous, or xanthomatosis; a secondary defect such as Zellweger's syndrome, neonatal hepatitis, cystic fibrosis, manifestations in the liver, ALGS (Alagilles syndrome), PFIC (progressive familial intrahepatic cholestasis, autoimmune hepatitis, primary biliary cirrhosis (PBC), liver fibrosis, non alcoholic fatty liver disease, NAFLD/NASH, portal hypertension, general cholestasis such as in jaundice due to drugs or during pregnancy, intra and extrahepatic cholestasis such as hereditary forms of cholestasis such as PFIC1, Primary sclerosing cholangitis, gall stones and choledocholithiasis, malignancy causing obstruction of

the biliary tree, symptoms (scratching, pruritus) due to cholestasis/jaundice, pancreatitis, chronic autoimmune liver disease leading to progressive cholestasis, and pruritus of cholestatic liver disease.

[0078] Further examples of liver diseases as disclosed herein include a hepatic disorder or a hepatic related condition, fatty liver, hepatic steatosis, non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute fatty liver, fatty liver of pregnancy, drug-induced hepatitis, iron overload disorders, hepatic fibrosis, hepatic cirrhosis, hepatoma, viral hepatitis and problems in relation to tumours and neoplasmas of the liver, of the biliary tract and of the pancreas.

Combination with other active substances

[0079] Further disclosed herein is an IBAT inhibitor according to formula (I) or Formula (II) as defined above, in combination with at least one other therapeutically active substance. The at least one other therapeutically active substance may be an IBAT inhibitor compound.

Incretines and hormones produced by the L cells

[0080] The at least one other therapeutically active substance may be an Incretine or a hormone produced by the L cells.

[0081] In one aspect, the at least one other therapeutically active substance is a L-cell endocrine peptide enhancer such as a GLP-1 enhancer. Examples of a GLP-1 enhancer are GLP-1, a GLP-1 secretion enhancer, a GLP-1 degradation inhibitor, or a combination thereof.

[0082] In one aspect, the L-cell endocrine peptide enhancer is a GLP-2 enhancer such as GLP-2, a GLP-2 secretion enhancer, a GLP-2 degradation inhibitor, or a combination thereof.

[0083] In one aspect the L-cell endocrine peptide enhancer is a PYY enhancer such as an oxyntomodulin enhancer.

Incretin Mimetics

[0084] In one aspect, the at least one other therapeutically active substance is an incretin mimetic such as exenatide (Byetta®).

[0085] Also disclosed is an oral combination of an IBAT inhibitor of Formula (I) or Formula (II) as disclosed herein and a DPP-IV inhibitor.

Enteroendocrine Peptides

[0086] In one aspect, the at least one other therapeutically active substance is an enteroendocrine peptide such as GLP-1 or GLP-1 analogs, for example Taspoglutide® (Ipsen), or the like.

Combination Therapy with an IBAT inhibitor and a DPP-IV Inhibitor

[0087] In one aspect, the at least one other therapeutically active substance is a DPP-IV inhibitor.

[0088] Also disclosed is a combination of an IBAT-inhibitor and metformin and/or sitagliptin (Janumet®) and/or DPP-IV inhibitors suitable for use with the methods described herein include but are not limited to (2S)-1-{2-[(3-hydroxy-1-adamantyl)amino]-acetyl}pyrrolidine-2-carbonitrile (vildagliptin), (3R)-3-amino-1-[9-(trifluoromethyl)-1,4,7,8-tetrazabicyclo[4.3.0]nona-6,8--dien-4-yl]-4-(2,4,5-trifluorophenyl)butan-1-one (sitagliptin), (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile (saxagliptin), and 2-[(6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-2(1H)-yl)methyl]benzonitrile (alogliptin).

TGR5 Receptor Modulators

[0089] In one aspect, the at least one other therapeutically active substance is a TGR5 agonist. TGR5 modulators (e.g. agonists) include, but are not limited to, the compounds described in WO 2008/091540, WO 2008/067219 and U.S. Appl. No. 2008/0221161.

Thiazolidinediones

[0090] In one embodiment, the at least one other therapeutically active substance is a thiazolidinedione such as Rosiglitazone (Avandia), Pioglitazone (Actos), Troglitazone (Rezulin), MCC-555, rivoglitazone, ciglitazone or the like.

[0091] It is disclosed that an IBAT INHIBITOR of Formula (I) or Formula (II) as described herein, may be administered in combination with a DPP-IV inhibitor and/or a biliary shunt. Examples of biliary shunts include but are not limited to shunts described in WO 2007/0050628.

[0092] As used herein, the term "additive effect" describes the combined effect of two (or more) pharmaceutically active agents that is equal to the sum of the effect of each agent given alone. A synergistic effect is one in which the combined effect of two (or more) pharmaceutically active agents is greater than the sum of the effect of each agent given alone. Any suitable combination of an ASBTI with one or more of the aforementioned other active ingredients and optionally with one or more other pharmacologically active substances is contemplated as being within the scope of the methods described herein.

[0093] In some embodiments, the particular choice of compounds depends upon the diagnosis of the attending physicians and their judgment of the condition of the individual and the appropriate treatment protocol. The compounds are optionally administered concurrently (e.g., simultaneously, essentially simultaneously or within the same treatment protocol) or sequentially, depending upon the nature of the disease, disorder, or condition, the condition of the individual, and the actual choice of compounds used. In certain instances, the determination of the order of administration, and the number of repetitions of administration of each therapeutic agent during a treatment protocol, is based on an evaluation of the disease being treated and the condition of the individual.

[0094] In some embodiments, therapeutically-effective dosages vary when the drugs are used in treatment combinations. Methods for experimentally determining therapeutically-effective dosages of drugs and other agents for use in combination treatment regimens are described in the literature.

[0095] In some embodiments of the combination therapies described herein, dosages of the co-administered compounds vary depending on the type of co-drug employed, on the specific drug employed, on the disease or condition being treated and so forth. In addition, when co-administered with one or more biologically active agents, the compound provided herein is optionally administered either simultaneously with the biologically active agent(s), or sequentially. In certain instances, if administered sequentially, the attending physician will decide on the appropriate sequence of therapeutic compound described herein in combination with the additional therapeutic agent.

[0096] The multiple therapeutic agents (at least one of which is a therapeutic compound described herein) are optionally administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents are optionally provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). In certain instances, one of the therapeutic agents is optionally given in multiple doses. In other instances, both are optionally given as multiple doses. If not simultaneous, the timing between the multiple doses is any suitable timing, e.g., from more than zero weeks to less than four weeks. In addition, the combination methods, compositions and formulations are not to be limited to the use of only two agents; the use of multiple therapeutic combinations are also envisioned (including two or more compounds described herein).

[0097] In certain embodiments, a dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought, is modified in accordance with a variety of factors. These factors include the disorder from which the subject suffers, as well as the age, weight, sex, diet, and medical condition of the subject. Thus, in various embodiments, the dosage regimen actually employed varies and deviates from the dosage regimens set forth herein.

[0098] In some embodiments, the pharmaceutical agents which make up the combination therapy described herein are provided in a combined dosage form or in separate dosage forms intended for substantially simultaneous administration. In certain embodiments, the pharmaceutical agents that make up the combination therapy are administered sequentially, with either therapeutic compound being administered by a regimen calling for two-step administration. In some embodiments, two-step administration regimen calls for sequential administration of the active agents or spaced-apart administration of the separate active agents. In certain embodiments, the time period between the multiple administration steps varies, by way of example, from a few minutes to several hours, depending upon the properties of each pharmaceutical agent, such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the pharmaceutical agent.

[0099] Also disclosed are IBAT inhibitor compounds described herein in combination with at least one bile acid binder e.g. a resin such as cholestyramine, cholestipol and colesevelam.

Bile acid binders (bile acid sequestrants, resins)

[0100] It is disclosed that an IBAT inhibitor of formula (I) or Formula (II) as defined above, may be administered as a pharmaceutical formulation also comprising at least one bile acid binder, said formulation being designed to deliver the bile acid binder in the colon and the IBAT inhibitor in the small intestine.

[0101] Examples of useful bile acid binders are Cholestyramine, which is a hydrophilic polyacrylic quaternary ammonium anion exchange resin, known to be effective in reducing blood cholesterol levels. Cholestyramine, and various

compositions including cholestyramine, are described, for example, in British Pat Nos. 929,391 and 1,286, 949; and U. S. Patent Nos. 3,383, 281; 3,308, 020; 3,769, 399; 3,846, 541; 3,974, 272; 4,172, 120; 4,252, 790; 4,340, 585; 4,814, 354; 4,874, 744; 4,895, 723; 5,695, 749; and 6,066, 336. Cholestyramine is commercially available from Novopharm, USA Inc (Questrans Light), Upsher-Smith (PREVALITE (D), and Apothecon. As used herein, "cholestyramine" includes any such composition comprising cholestyramine, or pharmaceutically acceptable salts thereof. These are also called Questrans™

Questran Light Questrans Light (cholestyramine) is a non-absorbable anion binding resin FDA approved for the treatment of hypercholesterolemia.

[0102] An amine polymer having a first substituent, bound to a first amine of the amine polymer, that includes a hydrophobic aliphatic moiety, and a second substituent, bound to a second amine of the amine polymer, that includes an aliphatic quaternary amine-containing moiety as described in USP 5,693,675 and 5,607,669.

[0103] The salt of an alkylated and cross linked polymer comprising the reaction product of: (a) one or more cross linked polymers, or salts and copolymers thereof having a repeat unit selected from the group consisting of: $(\text{NR}-\text{CH}_2\text{CH}_2)_n$ (2) and $(\text{NR}-\text{CH}_2\text{CH}_2-\text{NR}-\text{CH}_2\text{CH}_2-\text{NR}-\text{CH}_2\text{CHOH}-\text{CH}_2)_n$ (3) where n is a positive integer and each R, independently, is H or a C1-C8 alkyl group; (b) at least one aliphatic alkylating agent, said reaction product characterized in that: (i) at least some of the nitrogen atoms in said repeat units unreacted with said alkylating agent; (ii) less than 10 mol percent of the nitrogen atoms in said repeat units reacting with said alkylating agent forming quaternary ammonium units; and (iii) a fixed positive charge and one or more counter ions, such as Colesevelam and colesevelam hydrochloride.

[0104] Useful bile acid binders are resins, such as cholestyramine and cholestipol. One advantage is that the dose of bile acid binder might be kept lower than the therapeutic dose for treatment of cholesterolaemia in single treatment comprising solely a bile acid binder. By a low dose of bile acid binder any possible side effects caused by poor tolerance of the patient to the therapeutic dose could also be avoided.

[0105] Another useful bile acid binder is a water insoluble non-toxic polymeric amine having a molecular weight in excess of 3,000, having the property of binding at least 30% of the available glycocholic acid within 5 minutes when exposed to an aqueous solution of an equal weight of said acid, having a polymer skeleton inert to digestive enzymes, and having a water content greater than 65% after equilibration with air at 100% relative humidity, e.g., cholestipol described in USP 3,383,281,

[0106] In a further aspect, a suitable bile acid binder is one of cholestyramine, cholestipol or colesevelam.

[0107] A preferred aspect is the use of colesevelam as the bile acid binder.

[0108] The compositions may further comprise statins e.g an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier.

[0109] Also disclosed is a combined oral pharmaceutical formulation comprising an IBAT inhibitor compound of formula (I) or Formula (II) as defined above or a pharmaceutically acceptable salt thereof and a bile acid binder or a pharmaceutically acceptable salt thereof, said formulation being designed to deliver the bile acid binder in the colon and the IBAT inhibitor in the small intestine.

[0110] Also disclosed is a pharmaceutical formulation comprising a core of a bile acid binder formulated for release in the colon, surrounded by an outer layer comprising an IBAT inhibitor of formula (I) or Formula (II) as defined above, and formulated for immediate release or for delayed release in the distal jejunum or the proximal ileum.

Statins

[0111] It is disclosed that an IBAT inhibitor compound e.g. a compound of formula (I) or formula (II) as defined above or a pharmaceutically acceptable salt thereof, may be administered in association with an HMG Co-A reductase inhibitor, or pharmaceutically acceptable salts thereof. Suitable HMG Co-A reductase inhibitors, pharmaceutically acceptable salts thereof are statins well known in the art. Particular statins are fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, dalvastatin, mevastatin and (E)-7- [4- (4-fluorophenyl)-6-isopropyl-2- [methyl (methylsulphonyl) amino] pyrimidin-5-yl] (3R, 5S)-3,5-dihydroxyhept-6-enoic acid (rosuvastatin), or a pharmaceutically acceptable salt thereof. A particular statin is atorvastatin, or a pharmaceutically acceptable salt thereof. A more particular statin is atorvastatin calcium salt. A further particular statin is (E)-7- [4- (4-fluorophenyl)-6-isopropyl-2- [methyl (methylsulphonyl) amino] pyrimidin-5-yl] (3R, 5S)-3,5-dihydroxyhept-6-enoic acid (rosuvastatin), or a pharmaceutically acceptable salt thereof. Other particular statin are rosuvastatin calcium salt and pitavastatin (HMG Co A reductase).

[0112] It is disclosed that the compound of formula (I) or formula (II) as defined above, or a pharmaceutically acceptable salt thereof may be administered in association with an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt thereof, and/or a bile acid binder thereby avoiding a possible risk of excess of bile acids in colon caused by the inhibition of the ileal bile acid transport system. An excess of bile acids in the visceral contents may cause diarrhoea.

[0113] An HMG CoA-reductase inhibitor, or a pharmaceutically acceptable salt thereof will by its action decrease the endogenous cholesterol available for the bile acid synthesis and have an additive effect in combination with a compound of formula (I) or formula (II) as defined above, or a pharmaceutically acceptable salt thereof on lipid lowering.

[0114] The composition may further comprise a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt thereof.

A CETP (cholesteryl ester transfer protein) inhibitor, for example those referenced and described in WO 00/38725 page 7 line 22-page 10, line 17.

A cholesterol absorption antagonist for example azetidinones such as SCH 58235 and those described in US 5,767,115; MTP (microsomal transfer protein) inhibitor for example those described in Science, 282,751-54, 1998;

A fibric acid derivative; for example clofibrate, gemfibrozil, fenofibrate, ciprofibrate and bezafibrate;

A nicotinic acid derivative, for example, nicotinic acid (niacin), acipimox and niceritrol ;

A phytosterol compound for example stanols ;

Probucol ;

An anti-obesity compound for example orlistat (EP 129,748) and sibutramine (GB 2,184,122 and US 4,929,629);

An antihypertensive compound for example an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, an adrenergic blocker, an alpha adrenergic blocker, a beta adrenergic blocker, a mixed alpha/beta adrenergic blocker, an adrenergic stimulant, calcium channel blocker, a diuretic or a vasodilator;

Insulin;

Sulphonylureas including glibenclamide and/or tolbutamide.

Biguanides

[0115] In some embodiments, the additional therapeutic agent is a biguanide. In some instances, biguanides reduce blood and/or plasma glucose levels. Examples of biguanides include metformin, buformin, phenformin, proguanil or the like.

[0116] Acarbose; or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

Angiotensin II antagonists

[0117] Preferred angiotensin II antagonists, pharmaceutically acceptable salts thereof for use in combination with a compound of formula (I) include the compounds: candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan and eprosartan. Particularly preferred angiotensin II antagonists or pharmaceutically acceptable derivatives thereof are candesartan and candesartan cilexetil.

[0118] PPAR alpha and/or gamma and/or delta agonists or a pharmaceutical acceptable salt thereof.

It is disclosed that the IBAT inhibitor compound, or a pharmaceutically acceptable salt thereof, may be administered in association with a PPAR alpha and/or gamma agonist, or pharmaceutically acceptable salts thereof. Suitable PPAR alpha and/or gamma agonists, pharmaceutically acceptable salts thereof are well known in the art. These include the compounds described in WO 01/12187, WO 01/12612, WO 99/62870, WO 99/62872, WO 99/62871, WO 98/57941, WO 01/40170, J Med Chem, 1996,39,665, Expert Opinion on Therapeutic Patents, 10 (5), 623-634 (in particular the compounds described in the patent applications listed on page 634) and J Med Chem, 2000,43,527. Particularly a PPAR alpha and/or gamma agonist refers to WY-14643, clofibrate, fenofibrate, bezafibrate, GW 9578, troglitazone, pioglitazone, rosiglitazone, eglitazone, proglitazone, BRL-49634, KRP-297, JTT-501, SB 213068, GW 1929, GW 7845, GW 0207, L-796449, L-165041 and GW 2433.

[0119] Particularly a PPAR alpha and/or gamma agonist refers to (S)-2-ethoxy-3-[4-(2-{4-methanesulphonyloxyphenyl} ethoxy) phenyl] propanoic acid and pharmaceutically acceptable salts thereof.

[0120] It is disclosed that the compound of formula (I) or formula (II) as defined above may be used together with one or more antidiabetics hypoglycaemic active ingredients, cholesterol absorption inhibitors, PPAR delta agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP-citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, HM74A receptor agonists, lipase inhibitors, insulins, sulphonylureas, biguanides, meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, active ingredients which act on the ATP-dependent potassium channel of the beta cells, glycogen phosphorylase inhibitors, glucagon receptor antagonists, activators of glucokinase, inhibitors of gluconeogenesis, inhibitors of fructose-1,6-bisphosphatase, modulators of glucose transporter 4, inhibitors of glutamine-fructose-6-phosphate amidotransferase, inhibitors of dipeptidylpeptidase IV, inhibitors of 11-beta-hydroxysteroid dehydrogenase 1, inhibitors of protein tyrosine phosphatase 1 B, modulators of the sodium-dependent glucose transporter 1 or 2, modulators of GPR40, inhibitors of hormone-sensitive lipase, inhibitors of acetyl-CoA carboxylase, inhibitors of phosphoenolpyruvate carboxykinase, inhibitors of glycogen synthase kinase-3 beta, inhibitors of protein kinase C beta, endothelin-A receptor antagonists, inhibitors of I kappaB kinase, modulators of the glucocorticoid receptor, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, beta 3 agonists, CB1 receptor antagonists, MSH (melanocyte-stimulating hormone) agonists, CCK

agonists, serotonin reuptake inhibitors, mixed serotonergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-beta agonists or amphetamines.

[0121] It is disclosed that an IBAT inhibitor of Formula (I) or Formula (II) as defined above, may be administered in combination with a second therapeutic agent selected from a DPP-IV inhibitor, a thiazolidinedione, or an analogue thereof, or a TGR5 agonist.

[0122] It is disclosed that IBAT inhibitor compounds described herein may be combined with or utilized in combination with one or more of the following therapeutic agents in any combination: insulin, insulin-mimetics, DPP-IV inhibitors, or TGR5 modulators.

[0123] Further active substances to be combined with one or more IBAT inhibitors of the invention may be chosen from one or more of the following substances:

Ursodeoxycholic acid; nor-ursodeoxycholic acid; Rifampicin and related rifamycin derivatives as described in US 3,342,810; opiate antagonists such as Naloxone and Naltrexone; serotonin antagonists such as 5-HT₃ receptor antagonists and 5-HT₂ antagonists, e.g. Trazodone, Nefazodone, Amoxapine, Clozapine; antihistamines such as Brompheniramine, Chlorpheniramine Dimenhydrinate, Diphenhydramine, Doxylamine Loratadine Cetirizine; serotonin reuptake inhibitors such as Citalopram, Dapoxetine, Escitalopram, Fluoxetine, Fluvoxamine, lisdalpine, Pparoxetine, Sertraline, Zimelidine; corticosteroids such as glucocorticoids and mineralocorticoids e.g. chosen from Hydrocortisone (Cortisol), Cortisone and acetate, Prednisone, Prednisolone, Methylprednisolone, Dexamethasone, Betamethasone, Triamcinolone, Beclometasone, Fludrocortisone and acetate, Deoxycorticosterone and acetate (DOCA) Aldosterone.

[0124] Examples of PPAR delta agonists are GW-501516 (501516, GSK-516, GW-516, GW-1516; a peroxisome proliferator-activated receptor (PPAR)-delta agonist, and several other compounds developed from GW-501516, including GI-262570, GW-0072, GW-7845 and GW-7647.

[0125] It is disclosed that the IBAT inhibitor may be combined with one or more of Atreleuton, Eprotirome, Losmapimod, Ezetimibe (SCH58235) Bezafibrate, Fenofibrate, Varespladib, Darapladib, Lomitapide, Implipapide, Rosiglitazone, Dalcetapib, Anacetrapib, Lorcaserin, Dapagliflozin, Canagliflozin, Sertgliflozin ASP-1941 Orlistat, Pioglitazone, Sodelglitazar, Netoglitazone, Indegliptaz, Navegliptaz, Lobegliptazone, Alegliptaz, Bromocriptine, Tesofensine, Monoamine, Alogliptin, Vildagliptin, Saxagliptin, Sitagliptin, Denagliptin, Gemigliptin, Linagliptin, Dutogliptin, Teneligliptin, LC-150444, Laropiprant extended release niacin, Simvastatin ezetimibe, Rosuvastatin fenofibrate, Rosuvastatin ezetimibe and Atorvastatin ezetimibe.

[0126] Combinations with Tredaptive, Vytorin and Certrid may be used.

[0127] According to one embodiment the IBAT inhibitor may be combined with one or more of any of the above mentioned other compounds.

[0128] It is disclosed that the IBAT inhibitors may be combined with at least one other active substance selected from dipeptidyl peptidase-IV-inhibitors, PPAR γ agonists, statins and bile acid binders in any combination.

[0129] It is disclosed that the IBAT inhibitors may be combined with at least one DPP-IV, at least one PPAR γ agonist, such as Sitagliptin and Pioglitazone.

[0130] It is disclosed that the IBAT inhibitors may be combined with at least one DPP-IV and at least one statin e.g. Sitagliptin and Simvastatin.

[0131] Another active substance which may be combined with the IBAT inhibitors of the invention is ursodeoxycholic acid.

Carriers and excipients

[0132] The compositions of the invention may further comprise a pharmaceutically acceptable diluent or carrier.

[0133] Pharmaceutical compositions may be formulated as known in the art using one or more physiologically acceptable carriers including, e.g., excipients and depending on the route of administration chosen.

[0134] A carrier includes, in some embodiments, a pharmaceutically acceptable excipient and is selected on the basis of compatibility with compounds described herein, such as, compounds of any of Formula I and II, and the release profile properties of the desired dosage form.

Exemplary carrier materials include, e.g., binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents.

[0135] Pharmaceutical compositions and carriers are described, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975; Liberman, H. A. and Lachman, L., Eds., Pharmaceutical

Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999).

[0136] A mixture of a compound of Formula I and II and possibly also other active compounds mentioned herein, with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients may be formulated into a composition. In certain embodiments, therapeutically effective amounts of compounds described herein are administered in a pharmaceutical composition to an individual having a disease, disorder, or condition to be treated. In specific embodiments, the individual is a human. The compounds described herein are either utilized separately or in combination with one or more additional therapeutic agents.

[0137] In certain embodiments, the pharmaceutical formulations described herein are administered to an individual in any manner, including one or more of multiple administration routes, such as, by way of example, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes.

[0138] The pharmaceutical compositions described herein are formulated as a dosage form. As such, in some embodiments, provided herein does a dosage form comprise a compound described herein, suitable for administration to an individual. In certain embodiments, suitable dosage forms include, by way of example, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations.

[0139] The pharmaceutical solid dosage forms described herein optionally include an additional therapeutic compound described herein and one or more pharmaceutically acceptable additives such as a compatible carrier, binder, filling agent, suspending agent, flavouring agent, sweetening agent, disintegrating agent, dispersing agent, surfactant, lubricant, colorant, diluent, solubilizer, moistening agent, plasticizer, stabilizer, penetration enhancer, wetting agent, anti-foaming agent, antioxidant, preservative, or one or more combination thereof. In some aspects, using standard coating procedures, such as those described in Remington's Pharmaceutical Sciences, 20th Edition (2000), a film coating is provided around the formulation of the compound of Formula I-II. In one embodiment, a compound described herein is in the form of a particle and some or all of the particles of the compound are coated. In certain embodiments, some or all of the particles of a compound described herein are microencapsulated. In some embodiments, the particles of the compound described herein are not microencapsulated and are uncoated.

Dosage forms

[0140] The pharmaceutical solid dosage forms may optionally include additional therapeutic compounds and one or more pharmaceutically acceptable additives such as a compatible carrier, binder, filling agent, suspending agent, flavouring agent, sweetening agent, disintegrating agent, dispersing agent, surfactant, lubricant, colorant, diluent, solubilizer, moistening agent, plasticizer, stabilizer, penetration enhancer, wetting agent, anti-foaming agent, antioxidant, preservative, or one or more combination thereof. In some aspects, using standard coating procedures, such as those described in Remington's Pharmaceutical Sciences, 20th Edition (2000), a film coating is provided around the formulation of the compound of Formula I-II. In one embodiment, a compound described herein is in the form of a particle and some or all of the particles of the compound are coated. In certain embodiments, some or all of the particles of a compound described herein are microencapsulated. In some embodiments, the particles of the compound described herein are not microencapsulated and are uncoated.

[0141] A dosage form comprises a matrix that allows for controlled release of an active agent in the distal jejunum, proximal ileum, distal ileum and/or the colon. In some embodiments, a dosage form comprises a polymer that is pH sensitive (e.g., a MMX.TM. matrix from Cosmo Pharmaceuticals) and allows for controlled release of an active agent in the ileum and/or the colon. Examples of such pH sensitive polymers suitable for controlled release include and are not limited to polyacrylic polymers (e.g., anionic polymers of methacrylic acid and/or methacrylic acid esters, e.g., Carbopol.RTM. polymers, (CAS number 9063-87-0;) that comprise acidic groups (e.g., -COOH, -SO₃H) and swell in basic pH of the intestine (e.g., pH of about 7 to about 8). In some embodiments, a dosage form suitable for controlled release in the distal ileum comprises microparticulate active agent (e.g., micronized active agent). In some embodiments, a non-enzymatically degrading poly(DL-lactide-co-glycolide) (PLGA) core is suitable for delivery of an IBAT to the distal ileum. In some embodiments, a dosage form comprising an IBAT is coated with an enteric polymer (e.g., Eudragit.RTM. S-100, cas number 25086-15-1), cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethylcellulose phthalate, anionic polymers of methacrylic acid, methacrylic acid esters or the like) for site specific delivery to the ileum and/or the colon. In some embodiments, bacterially activated systems are suitable for targeted delivery to the ileum. Examples of micro-flora activated systems include dosage forms comprising pectin, galactomannan, and/or Azo hydrogels and/or glycoside conjugates (e.g., conjugates of D-galactoside, beta -D-xylopyranoside or the like) of the active agent. Examples of gastrointestinal micro-flora enzymes include bacterial glycosidases such as, for example, D-galactosidase, beta-D-glucosidase, alpha-L-arabinofuranosidase, beta-D-xylopyranosidase or the like.

[0142] Coated units may be filled into hard gelatine capsules or mixed with tablet excipients, such as fillers, binders, disintegrants, lubricants and other pharmaceutically acceptable additives, and be compressed into tablets. The compressed tablet is optionally covered with film-forming agents to obtain a smooth surface of the tablet and further enhance the mechanical stability of the tablet during packaging and transport. Such a tablet coat, which may be applied on a multiple unit tablet or a conventional tablet, may further comprise additives like anti-tacking agents, colorants and pigments or other additives to improve the tablet appearance.

[0143] Suitable drugs for the new formulations are IBAT inhibitor compounds such as described in the above-discussed documents.

[0144] The IBAT inhibitor compound could alternatively be a low permeability drug as defined in the Biopharmaceutical Classification System proposed by FDA.

Dosage

[0145] The compound of formula (II), or a pharmaceutically acceptable salt thereof, will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg or 0.01-50 mg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient. Preferably a daily dose in the range of 1-50 mg is employed. In another aspect a daily dose in the range of 0.02-20 mg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated.

Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

[0146] The size of the dose required for the therapeutic or prophylactic treatment will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit dose in the range, for example, 1-100, preferably 1-50 is envisaged. The daily dose can be administered as a single dose or divided into one, two, three or more unit doses.

[0147] A pharmaceutical formulation according to the present invention with a targeted delivery in the gastro intestinal tract provides a reduced systemic exposure, as can be measured by the area under the drug plasma concentration versus time curve (AUC) or 7 α -hydroxy-4-cholesten-3-one (C4), while maintaining or even increasing the therapeutic effect, as e.g. measured by serum cholesterol reduction.

[0148] A combination therapy comprising an IBAT inhibitor and a bile acid binder comprises preferably a low daily dose of the bile acid binder, such as less than 5 g of a resin, and more preferably less than 2 g. A dosage form with colon release of the bile acid binder could be constructed by any of the above described principles for delayed release formulations.

[0149] A combination therapy comprising an IBAT inhibitor and a bile acid binder may comprise a low daily dose of the bile acid binder, such as less than 5 g of a resin, and more preferably less than 4, 3, 2 or less than 1 g. Suitable ranges may be 0.1-5 g, 0.5- 4 g, 1-3 g, 2-4 g, 2-3 g per day. A dosage form with colon release of the bile acid binder could be constructed by any of the above described principles for delayed release formulations.

[0150] A tablet may consist of an inner core of 1-1000 mg, e.g. 200-800 mg, 10-400mg, 10-200mg or 20-80 mg acid binder in a colonic delivery formulation and an outer lamina with 1-100 mg, 5-50 mg e.g. 1-20 mg of an IBAT inhibitor.

[0151] The daily dose of IBAT inhibitor and /or bile acid binder can be administered as a single dose or divided into one, two, three or more unit doses.

[0152] Dosing three times a day with 400 mg of colessevelam in a colonic release formulation will give an adequate binding of bile acids in the colon as the total luminal volume is expected to be about 100 ml, which is in accordance to an accepted pharmacokinetic calculation volume of 250 to 300 ml for the small gut. The daily recommended total dose of colessevelam to block bile acid absorption in total gut of humans is 3750 mg/day.

[0153] The following contemplated Examples are intended to illustrate the invention.

[0154] The expression "comprising" as used herein should be understood to include, but not be limited to, the stated items.

Example 1

[0155] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)- α -[N-(carboxymethyl)carbamoyl] benzyl} carbamoyl-methoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, Mw. 696,89.

[0156] This compound is prepared as described in Example 2 of WO3022286.

Example 2

[0157] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N-((R)- α -[N'-((S)-1-carboxyethyl) carbamoyl] benzyl} car-

bamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine, Mw. 709,92.

[0158] This compound is prepared as described in Example 2 of WO03106482.

Example 3

[0159] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl) carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, Mw. 724,94.

[0160] This compound is prepared as described in Example 6 of WO3022286.

Example 4

[0161] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((R)-1-carboxy-2-methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, Mw. 757,01.

[0162] This compound is prepared as described in Example 7 of WO3022286.

Example 5

[0163] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, Mw. 740,94.

[0164] This compound is prepared as described in Example 29 of WO3022286.

Example 6

[0165] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((R)-1-carboxy-2-methylthioethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, Mw. 773,00.

[0166] This compound is prepared as described in Example 30 of WO3022286.

Example 7

[0167] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, Mw. 738,97.

[0168] This compound is prepared as described in Example 15 of WO3022286.

Example 8

[0169] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, Mw. 756,94.

[0170] This compound is prepared as described in Example 26 of WO3022286.

Example 9

[0171] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxybutyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, Mw. 754,97.

[0172] This compound is prepared as described in Example 28 of WO3022286.

Example 10

[0173] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxyethyl) carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, Mw. 710,91.

[0174] This compound is prepared as described in Example 5 of WO3022286.

Example 11

[0175] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*'-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine, Mw. 739,95.

[0176] This compound is prepared as described in Example 1 of WO3022286.

Example 12

[0177] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, Mw. 726,91.

[0178] This compound is prepared as described in Example 11 of WO3022286.

Example 13

[0179] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, Mw. 754,97.

[0180] This compound is prepared as described in Example 27 of WO3022286.

Example 14

[0181] 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N*'-(carboxymethyl) carbamoyl] methyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine, Mw. 695,90.

[0182] This compound is prepared as described in Example 43 of WO0250051.

Example 15Pharmaceutical effect Mean Inhibitory effect (%)

[0183] ISBT Hu HEK Uptake SPA 13203 IBAT HUM Ileal Bile Acid Transporter Human HEK Glycocholic acid Uptake Radiometric - SPA Inhibitor IC50 Mean IC50 (nM) was determined for the compounds of examples 1-14

Test systemAnimals

[0184] Species Mouse; Strain ApoE knock out; Sub strain C57BL/6; Sex Female; Total No. of animals 70; Body weight range 20 g to 22 g; Supplier Møllegaard's Breeding (Skensved, Denmark); Identification method ID cards (bar code).

[0185] Acclimatisation At least one week at the Section of Laboratory; Animal Resource at AstraZeneca; Housing conditions Kept five by five in cages (Makrolon III, 7 dm²) in a room with regulated temperature (22°C), relative humidity (40% to 60%) and a 12/12 hours light/dark cycle. Diet Free access to R3 pellets (Lactamin, Vadstena, Sweden) during the housing and experimental period. Water, free access to tap water during the housing and experimental period.

[0186] Bedding Sprinkle bedding of aspen wood (Tapvei, Finland).

Experimental procedures

[0187] The animals were orally administered vehicle (n=3) or the compound of Example 14 (0.156 (n=3), 0.625 (n=3) or 2.5 μ mol/kg (n=3)) at 13:00 o'clock on the experimental day. Thirty minutes later, a trace amount of ⁷⁵SeHCAT (⁷⁵Se-homo-tauro-cholic acid) (0.1 mCi per 0.1 mL per mouse) was orally given to each mouse. Twenty-four hours after ⁷⁵SeHCAT administration, the animals were killed by CO₂ inhalation. At sacrifice, the gall bladder and the whole intestine were removed, and the faeces during the 24-hour period after ⁷⁵SeHCAT administration was collected for each mouse. The gamma radioactivities of ⁷⁵SeHCAT in the faeces and in the gall bladder-intestine were separately counted by 1282 CompuGamma CS Gamma counter (Wallac oy, Turku, Finland). The stability as well as the quantity of the ⁷⁵SeHCAT administered to each mouse, were controlled with an additional ⁷⁵SeHCAT aliquot following the same experimental process as other tested samples in the study.








Data analysis

[0188] The sum of the gamma counts from both the faeces and the gall bladder-intestine was considered as the total recovered ⁷⁵SeHCAT, which was averaged around 85% of the total ⁷⁵SeHCAT administered to each mouse. Of the recovered radioactivity of ⁷⁵SeHCAT, the percentage of the ⁷⁵SeHCAT detected in the faeces was considered as the faecal excretion while that in the gall bladder-intestine as body retention. Inhibitory effect of the compound of Example 14 on ⁷⁵SeHCAT intestinal absorption was calculated following the ⁷⁵SeHCAT body retention and the faecal excretion, and the ED₅₀ of the compound was estimated following the dose-effect curve.








Results

[0189] The mean I BAT inhibitory effect (%) at a dose ($\mu\text{mol/kg}$): 0.156 was determined for the compounds of examples 1-14 and is reported in Table 1.

Table 1

Example	Structure	% inhibition 0.156 $\mu\text{mol/kg}$	Mean IC ₅₀ nM
1.		43	0,45
2.		55	0,39
3.		63	0,18
4.		63	0,35
5.		74	0,16
6.		59	-
7.		66	0,36

(continued)

Example	Structure	% inhibition 0.156 μ mol/kg	Mean IC ₅₀ nM
8.		46	0,11
9.		67	-
10.		68	0,2
11.		63	0,15
12.		63	0,3
13.		68	0,13
14.		28	1,2

Example 16**[0190]** In Vivo Animal Model of Primary sclerosing cholangitis (PSC)**[0191]** A genetic mice with targeted disruption of the Multidrug resistant *Mdr2* (*Abcb4*) gene encoding a canalicular phospholipid flippase (*Mdr2*^{-/-} mice) spontaneously develop sclerosing cholangitis with macroscopic and microscopic

features of human Primary sclerosing cholangitis. Bile duct injury in these mice is linked to defective biliary phospholipid secretion resulting in an increased concentration of free non-micellar bile acids which subsequently cause bile duct epithelial cell (cholangiocyte) injury, pericholangitis, periductal fibrosis with ductular proliferation and finally sclerosing cholangitis. Gene expression profiling has revealed remarkable similarities between *Mdr2*^{-/-} and human PSC. In analogy to the *Mdr2*^{-/-} mouse model of sclerosing cholangitis, Multidrug resistant protein *MDR3/ABCB4* (the human orthologue of rodent *Mdr2/Abcb4*) defects play a role in the pathogenesis of various cholangiopathies in humans. *MDR3* variants play a role as a modifier gene in the pathogenesis of various cholangiopathies such as PSC, Primary Biliary cirrhosis (PBC) and adulthood idiopathic ductopenia/ biliary fibrosis.

[0192] *Mdr2*^{-/-} mice were given daily oral doses of the compound of Example 14 by gavage for 2-4 weeks and controls were dosed the vehicle in the same way. Serum liver tests, liver histology and fibrosis were investigated. The compound of Example 14 improves liver tests, liver histology and fibrosis.

Example 17

[0193] A formulation for delayed release of the IBAT inhibitor having the following composition is prepared:

Substance	amount/capsule (mg)
IBAT inhibitor compound	
Example 14	10
Non pareil spheres	500
Ethyl cellulose	2
Hydroxypropylmethyl cellulose	10
Eudragit L 100-55 , CAS No: 25212 - 88 - 8	25
Triethylcitrate	2.4

[0194] The IBAT inhibitor compound of Example 14 is dissolved together with ethyl cellulose and hydroxypropyl cellulose in ethanol 99 %. The mixture is then sprayed onto the non-pareil spheres in a fluidized bed apparatus. Thereafter, the pellets are dried and aerated to remove residual ethanol. The Eudragit L 100-55 dispersion with addition of triethyl citrate is then sprayed onto the drug beads in a fluidized bed apparatus. Subsequently, the coated beads are filled in hard gelatine capsules after drying and sieving.

Example 18

[0195] A formulation for delayed release of the IBAT inhibitor having the following composition is prepared:

Ingredient	amount/tablet (mg)
IBAT inhibitor compound	
Example 14	10
Silicon dioxide	200
Povidone K-25	20
Eudragit FS30D, CAS no: 26936 - 24 - 3	30
Microcrystalline cellulose	250
Sodium stearyl fumarate	5

[0196] The IBAT inhibitor compound of Example 14 is suspended in water and sprayed onto silicon dioxide cores of a predefined size in a fluidized bed apparatus. The drug pellets are dried in an oven at 40°C for 24 h. Thereafter, a layer of Povidone K-25 is applied on the beads from an ethanolic solution in a fluidized bed apparatus. A final coat of Eudragit FS30D dispersion is applied thereafter in a fluidized bed. The coated beads are mixed with microcrystalline cellulose and sodium stearyl fumarate in a mixer and subsequently compressed to tablets.

Example 19

[0197] An IBAT inhibitor - colesevelam combination tablet with immediate release of the IBAT inhibitor and colon

EP 2 637 668 B1

release of the bile acid binder having the following composition is prepared:

	Ingredient	amount/tablet (mg)
5	<i>Core</i>	
	Colesevelam hydrochloride	400
	Microcrystalline cellulose	150
	Hydroxypropyl methyl cellulose	50
	Colloidal silicon dioxide	10
10	Magnesium stearate	5
	<i>Colon release layer</i>	
	Eudragit FS30D	60
	PlasACRYL T20, CAS no 123-94-4	6
15	<i>IBA T inhibitor layer</i>	
	IBAT inhibitor Example 14	7
	Hydroxypropylmethyl cellulose	12
	Croscarmellose sodium	6
	<i>Protective coating</i>	
20	Hydroxypropylmethyl cellulose	12
	Polyethylene glycol	2

[0198] Colesevelam hydrochloride, microcrystalline cellulose and colloidal silicon dioxide are mixed and granulated with hydroxypropyl methyl cellulose dissolved in water. The granules are dried and mixed with magnesium stearate and compressed to tablets. The EUDRAGIT FS30D dispersion and water are stirred into the PlasACRYL T20 and sprayed onto the core tablets using a suitable coating machine. The IBAT inhibitor coating suspension is prepared by mixing the IBAT inhibitor, hydroxypropyl methyl cellulose and croscarmellose sodium in water and sprayed onto the tablet cores with the colon release layer using a suitable coating machine. Finally the protective coating solution of hydroxypropyl-methyl cellulose and polyethylene glycol are sprayed onto the tablets using a suitable coating machine.

Example 20


[0199] A Colesevelam colon release tablet having the following composition is prepared:

	Ingredient	amount /tablet (mg)
35	<i>Core</i>	
	Colesevelam hydrochloride	400
	Microcrystalline cellulose	150
	Hydroxypropyl methyl cellulose	50
	Colloidal silicon dioxide	10
40	Magnesium stearate	5
	<i>Colon release layer</i>	
	Amylose	30
	Eudragit S100	60
45	Triethylcitrate	6
	Glycerolmonostearate	3

[0200] Colesevelam hydrochloride, microcrystalline cellulose and colloidal silicon dioxide are mixed and granulated with hydroxypropyl methyl cellulose dissolved in water. The granules are dried and mixed with magnesium stearate and compressed to tablets. Amylose, Eudragit 100, triethylcitrate and glycerolmonostearate are dissolved in suitable solvents and sprayed onto the tablet cores using a suitable coating machine.

Claims

1. A compound of formula II



Formula II

wherein

M is CH₂ or NH;

R¹ is H or hydroxy;

R² is H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃, or -CH₂CH₂SCH₃;

or a pharmaceutically acceptable salt thereof,

for use in the prophylaxis and/or treatment of a liver disease selected from the group consisting of Alagilles syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and pruritus of cholestatic liver disease.

2. The compound for use according to claim 1, wherein the compound of formula II is selected from the group consisting of:

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N-(carboxymethyl)carbamoyl]benzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(S)-1-carboxyethyl]carbamoyl]benzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(S)-1-carboxypropyl]carbamoyl]benzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(R)-1-carboxy-2-methylthioethyl]carbamoyl]benzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(S)-1-carboxypropyl]carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(R)-1-carboxy-2-methylthio-ethyl]carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(S)-1-carboxy-2-methylpropyl]carbamoyl]benzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(S)-1-carboxy-2-(R)-hydroxypropyl]carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(S)-1-carboxybutyl]carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(S)-1-carboxyethyl]carbamoyl]benzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(S)-1-carboxypropyl]carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiadiazepine;


1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(S)-1-carboxyethyl]carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N'-(S)-1-carboxy-2-methylpropyl]carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-1'-phenyl-1'-[N'-(carboxymethyl) carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine,

or a pharmaceutically acceptable salt thereof.

3. The compound for use according to claim 1 or 2, wherein the compound of formula II is 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)- α -[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, or a pharmaceutically acceptable salt thereof.
4. The compound for use according to claim 1 or 2, wherein the compound of formula II is 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-1'-phenyl-1'-[N'-(carboxymethyl)-carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine, or a pharmaceutically acceptable salt thereof.
5. The compound for use according to any one of claims 1 to 4, wherein the liver disease is Alagille syndrome (ALGS).
6. The compound for use according to any one of claims 1 to 4, wherein the liver disease is progressive familial intrahepatic cholestasis (PFIC).
7. The compound for use according to any one of claims 1 to 4, wherein the liver disease is primary biliary cirrhosis (PBC).
8. The compound for use according to any one of claims 1 to 4, wherein the liver disease is primary sclerosing cholangitis (PSC).
9. The compound for use according to any one of claims 1 to 4, wherein the liver disease is pruritus of cholestatic liver disease.
10. A pharmaceutical composition comprising a compound of Formula (II)



Formula II

wherein

M is CH₂ or NH;

R¹ is H or hydroxy;

R² is H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃, or -CH₂CH₂SCH₃;


or a pharmaceutically acceptable salt thereof,

for use in the prophylaxis and/or treatment of a liver disease selected from the group consisting of Alagilles syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and pruritus of cholestatic liver disease.

11. The pharmaceutical composition for use according to claim 10, wherein the compound of formula II is 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)- α -[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, or a pharmaceutically acceptable salt thereof.
12. The pharmaceutical composition for use according to claim 10, wherein the compound of formula II is 1,1-dioxo-

3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-1'-phenyl-1'-[N'-(carboxymethyl)carbamoyl]methyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine, or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical combination for simultaneous or sequential administration, which comprises a compound of formula II



Formula II

wherein

M is CH₂ or NH;


R¹ is H or hydroxy;

R² is H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃, or -CH₂CH₂SCH₃;

or a pharmaceutically acceptable salt thereof,

and ursodeoxycholic acid, for use in the prophylaxis and/or treatment of a liver disease selected from the group consisting of Alagilles syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and pruritus of cholestatic liver disease.

14. A pharmaceutical combination for simultaneous or sequential administration, which comprises a compound of formula II



Formula II

wherein

M is CH₂ or NH;

R¹ is H or hydroxy;

R² is H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃, or -CH₂CH₂SCH₃;

or a pharmaceutically acceptable salt thereof,


and nor-ursodeoxycholic acid, for use in the prophylaxis and/or treatment of a liver disease selected from the group consisting of Alagilles syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and pruritus of cholestatic liver disease.

15. The pharmaceutical combination for use according to claim 13 or 14, wherein the compound of formula II is 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical combination for use according to claim 13 or 14, wherein the compound of formula II is 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N*'-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine, or a pharmaceutically acceptable salt thereof.

Patentansprüche

1. Verbindung der Formel II,



Formel II

wobei es sich bei

M um CH₂ oder NH;

R¹ um H oder eine Hydroxylgruppe;

R² um H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃ oder -CH₂CH₂SCH₃ handelt,

oder ein pharmazeutisch verträgliches Salz davon,

zur Verwendung bei der Prophylaxe und/oder Behandlung einer Lebererkrankung, ausgewählt aus der Gruppe, die aus Alagille-Syndrom (ALGS), progressiver familiärer intrahepatischer Cholestase (PFIC), primär biliärer Zirrhose (PBC), primär sklerosierender Cholangitis (PSC) und Pruritus bei cholestatischer Lebererkrankung besteht.

2. Verbindung zur Verwendung nach Anspruch 1, wobei die Verbindung der Formel II aus der Gruppe ausgewählt ist, die aus Folgendem besteht:

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepin;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((R)-1-carboxy-2-methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((R)-1-carboxy-2-methylthioethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin;


1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-

hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin;
 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N*-((*S*)-1-carboxybutyl)carbamoyl]-4-hydroxybenzyl}
 carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin;
 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N*-((*S*)-1-carboxyethyl)carbamoyl]benzyl}carbamoyl-
 methoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin;
 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N*'-((*S*)-1-carboxypropyl)carbamoyl]-4-hydroxyben-
 zyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepin;
 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N*-((*S*)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}
 carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin;
 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N*-((*S*)-1-carboxy-2-methylpropyl)carbamoyl]-4-hy-
 droxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin und
 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)-1'-phenyl-1'-[*N*'-(carboxymethyl)carbamoyl]methyl}car-
 bamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepin

oder ein pharmazeutisch verträgliches Salz davon.

3. Verbindung zur Verwendung nach Anspruch 1 oder 2, wobei es sich bei der Verbindung der Formel II um 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N*-((*S*)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylme-
thoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin oder ein pharmazeutisch verträgliches Salz davon handelt.
4. Verbindung zur Verwendung nach Anspruch 1 oder 2, wobei es sich bei der Verbindung der Formel II um 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)-1'-phenyl-1'-[*N*'-(carboxymethyl)carbamoyl]methyl}carbamoylmetho-
xy)-2,3,4,5-tetrahydro-1,5-benzothiazepin oder ein pharmazeutisch verträgliches Salz davon handelt.
5. Verbindung zur Verwendung nach einem der Ansprüche 1 bis 4, wobei es sich bei der Lebererkrankung um das
Alagille-Syndrom (ALGS) handelt.
6. Verbindung zur Verwendung nach einem der Ansprüche 1 bis 4, wobei es sich bei der Lebererkrankung um pro-
gressive familiäre intrahepatische Cholestase (PFIC) handelt.
7. Verbindung zur Verwendung nach einem der Ansprüche 1 bis 4, wobei es sich bei der Lebererkrankung um primär
biliäre Zirrhose (PBC) handelt.
8. Verbindung zur Verwendung nach einem der Ansprüche 1 bis 4, wobei es sich bei der Lebererkrankung um primär
sklerosierende Cholangitis (PSC) handelt.
9. Verbindung zur Verwendung nach einem der Ansprüche 1 bis 4, wobei es sich bei der Lebererkrankung um Pruritus
bei cholestatischer Lebererkrankung handelt.
10. Pharmazeutische Zusammensetzung, umfassend eine Verbindung der Formel (II),



Formel II

wobei es sich bei

M um CH₂ oder NH;

R¹ um H oder eine Hydroxylgruppe;

R² um H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃ oder -CH₂CH₂SCH₃ handelt,

oder ein pharmazeutisch verträgliches Salz davon,


zur Verwendung bei der Prophylaxe und/oder Behandlung einer Lebererkrankung, ausgewählt aus der Gruppe, die aus Alagille-Syndrom (ALGS), progressiver familiärer intrahepatischer Cholestase (PFIC), primär biliärer Zirrhose (PBC), primär sklerosierender Cholangitis (PSC) und Pruritus bei cholestatischer Lebererkrankung besteht.

11. Pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 10, wobei es sich bei der Verbindung der Formel II um 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin oder ein pharmazeutisch verträgliches Salz davon handelt.

12. Pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 10, wobei es sich bei der Verbindung der Formel II um 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N*-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepin oder ein pharmazeutisch verträgliches Salz davon handelt.

13. Pharmazeutische Kombination zur gleichzeitigen oder sequenziellen Anwendung, welche Folgendes umfasst:

eine Verbindung der Formel II,



Formel II

wobei es sich bei

M um CH₂ oder NH;

R¹ um H oder eine Hydroxylgruppe;


R² um H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃ oder -CH₂CH₂SCH₃ handelt;

oder ein pharmazeutisch verträgliches Salz davon,

und Ursodeoxycholsäure, zur Verwendung bei der Prophylaxe und/oder Behandlung einer Lebererkrankung, ausgewählt aus der Gruppe, die aus Alagille-Syndrom (ALGS), progressiver familiärer intrahepatischer Cholestase (PFIC), primär biliärer Zirrhose (PBC), primär sklerosierender Cholangitis (PSC) und Pruritus bei cholestatischer Lebererkrankung besteht.

14. Pharmazeutische Kombination zur gleichzeitigen oder sequenziellen Anwendung, welche Folgendes umfasst:

eine Verbindung der Formel II,



Formel II

wobei es sich bei

M um CH₂ oder NH;

R¹ um H oder eine Hydroxylgruppe;

R² um H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃ oder -CH₂CH₂SCH₃ handelt;

oder ein pharmazeutisch verträgliches Salz davon,


und nor-Ursodeoxycholsäure, zur Verwendung bei der Prophylaxe und/oder Behandlung einer Lebererkrankung, ausgewählt aus der Gruppe, die aus Alagille-Syndrom (ALGS), progressiver familiärer intrahepatischer Cholestase (PFIC), primär biliärer Zirrhose (PBC), primär sklerosierender Cholangitis (PSC) und Pruritus bei cholestatischer Lebererkrankung besteht.

15. Pharmazeutische Kombination zur Verwendung nach Anspruch 13 oder 14, wobei es sich bei der Verbindung der Formel II um 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin oder ein pharmazeutisch verträgliches Salz davon handelt.

16. Pharmazeutische Kombination zur Verwendung nach Anspruch 13 oder 14, wobei es sich bei der Verbindung der Formel II um 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-((R)-1'-phenyl-1'-[N'-(carboxymethyl)carbamoyl]methyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepin oder ein pharmazeutisch verträgliches Salz davon handelt.

Revendications

1. Composé de formule II



Formule II

dans laquelle

M représente CH₂ ou NH ;

R¹ représente H ou un groupe hydroxy ;

R² représente H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃, ou -CH₂CH₂SCH₃ ; ou un sel pharmaceutiquement acceptable de celui-ci,

destiné à être utilisé pour la prophylaxie et/ou le traitement d'une maladie hépatique choisie dans l'ensemble constitué du syndrome d'Alagille (SAG), de la cholestase intra-hépatique familiale progressive (CIFP), de la cirrhose biliaire primitive (CBP), de la cholangite sclérosante primitive (CSP) et du prurit de maladie hépatique cholestatique.

2. Composé selon la revendication 1, le composé de formule II étant choisi dans l'ensemble consistant en :

1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N-(carboxyméthyl)carbamoyl]benzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ;
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxyéthyl]carbamoyl]benzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,5-benzothiazépine ;
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxypropyl]carbamoyl]benzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ;
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxy-2-méthylthioéthyl]carbamoyl]benzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ;
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxypropyl]carbamoyl]-4-hydroxybenzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ;
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxy-2-méthylthioéthyl]carbamoyl]-4-hydroxybenzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ;
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxy-2-méthylpropyl]carbamoyl]benzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ;
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxy-2-(R)-hydroxypropyl]carbamoyl]-4-hydroxybenzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ;
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxybutyl]carbamoyl]-4-hydroxybenzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ;
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxyéthyl]carbamoyl]benzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ;
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxypropyl]carbamoyl]-4-hydroxybenzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,5-benzothiazépine ;
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxyéthyl]carbamoyl]-4-hydroxybenzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ;
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxy-2-méthylpropyl]carbamoyl]-4-hydroxybenzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ; et
 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-1'-phényl-1'-[N'-(carboxyméthyl)carbamoyl]méthyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,5-benzothiazépine, ou un de leurs sels pharmaceutiquement acceptables.


3. Composé destiné à être utilisé selon la revendication 1 ou 2, le composé de formule II étant la 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N'-(S)-1-carboxypropyl]carbamoyl]-4-hydroxybenzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ou l'un de ses sels pharmaceutiquement acceptables.

4. Composé destiné à être utilisé selon la revendication 1 ou 2, le composé de formule II étant la 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-1'-phényl-1'-[N'-(carboxyméthyl)carbamoyl]méthyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,5-benzothiazépine ou l'un de ses sels pharmaceutiquement acceptables.

5. Composé destiné à être utilisé selon l'une quelconque des revendications 1 à 4, la maladie hépatique étant le syndrome d'Alagille (SAG).

6. Composé destiné à être utilisé selon l'une quelconque des revendications 1 à 4, la maladie hépatique étant la cholestase intra-hépatique familiale progressive (CIFP).

7. Composé destiné à être utilisé selon l'une quelconque des revendications 1 à 4, la maladie hépatique étant la cirrhose biliaire primitive (CBP).
8. Composé destiné à être utilisé selon l'une quelconque des revendications 1 à 4, la maladie hépatique étant la cholangite sclérosante primitive (CSP).
9. Composé destiné à être utilisé selon l'une quelconque des revendications 1 à 4, la maladie hépatique étant le prurit de maladie hépatique cholestatique.
10. Composition pharmaceutique comprenant un composé de formule II



Formule II

dans laquelle

M représente CH₂ ou NH ;

R¹ représente H ou un groupe hydroxy ;


R² représente H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃, ou -CH₂CH₂SCH₃ ; ou un sel pharmaceutiquement acceptable de celui-ci,

destinée à être utilisée dans la prophylaxie et/ou le traitement d'une maladie hépatique choisie dans l'ensemble constitué du syndrome d'Alagille (SAG), de la cholestase intra hépatique familiale progressive (CIFP), de la cirrhose biliaire primitive (CBP), de la cholangite sclérosante primitive (CSP) et du prurit de maladie hépatique cholestatique.

11. Composition pharmaceutique destinée à être utilisée selon la revendication 10, le composé de formule II étant la 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ou l'un de ses sels pharmaceutiquement acceptables.

12. Composition pharmaceutique destinée à être utilisée selon la revendication 10, le composé de formule II étant la 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(N-((R)-1'-phényl-1'-[N'-carboxyméthyl]carbamoyl)méthyl)carbamoylméthoxy)-2,3,4,5-tétrahydro-1,5-benzothiazépine ou l'un de ses sels pharmaceutiquement acceptables.

13. Combinaison pharmaceutique pour une administration simultanée ou séquentielle, qui comprend un composé de formule II



Formule II

dans laquelle


M représente CH₂ ou NH ;

R¹ représente H ou un groupe hydroxy ;

R² représente H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃, ou -CH₂CH₂SCH₃ ; ou un sel pharmaceutiquement acceptable de celui-ci,

et de l'acide ursodésoxycholique, destinée à être utilisée dans la prophylaxie et/ou le traitement d'une maladie hépatique choisie dans l'ensemble constitué du syndrome d'Alagille (SAG), de la cholestase intrahépatique familiale progressive (CIFP), de la cirrhose biliaire primitive (CBP), de la cholangite sclérosante primitive (CSP) et du prurit de maladie hépatique cholestatique.

14. Combinaison pharmaceutique pour une administration simultanée ou séquentielle, qui comprend un composé de formule II



Formule II

dans laquelle

M représente CH₂ ou NH ;

R¹ représente H ou un groupe hydroxy ;

R² représente H, CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH₂OH, -CH₂OCH₃, -CH(OH)CH₃, -CH₂SCH₃, ou -CH₂CH₂SCH₃ ; ou un sel pharmaceutiquement acceptable de celui-ci,

et de l'acide nor-ursodésoxycholique, destinée à être utilisée dans la prophylaxie et/ou le traitement d'une maladie hépatique choisie dans l'ensemble constitué du syndrome d'Alagille (SAG), de la cholestase intrahépatique familiale progressive (CIFP), de la cirrhose biliaire primitive (CBP), de la cholangite sclérosante primitive (CSP) et du prurit de maladie hépatique cholestatique.

15. Combinaison pharmaceutique destinée à être utilisée selon la revendication 13 ou 14, dans laquelle le composé de formule II est la 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(*N*-{(*R*)-*a*-[*N*-((*S*)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylméthoxy)-2,3,4,5-tétrahydro-1,2,5-benzothiadiazépine ou l'un de ses sels pharmaceutiquement acceptables.

5

16. Combinaison pharmaceutique destinée à être utilisée selon la revendication 13 ou 14, dans laquelle le composé de formule II est la 1,1-dioxo-3,3-dibutyl-5-phényl-7-méthylthio-8-(*N*-{(*R*)-1'-phényl-1'-[*N*'-carboxyméthyl)carbamoyl]méthyl}carbamoylméthoxy)-2,3,4,5-tétrahydro-1,5-benzothiazépine ou l'un de ses sels pharmaceutiquement acceptables.

10

15

20

25

30

35

40

45

50

55

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description


- WO 2008058630 A [0002]
- WO 2004089350 A [0003]
- EP 1535913 A [0004]
- WO 03106482 A [0005] [0158]
- WO 03022286 A [0005]
- WO 2008091540 A [0089]
- WO 2008067219 A [0089]
- US 20080221161 A [0089]
- WO 20070050628 A [0091]
- GB 929391 A [0101]
- GB 1286949 A [0101]
- US 3383281 A [0101] [0105]
- US 3308020 A [0101]
- US 3769399 A [0101]
- US 3846541 A [0101]
- US 3974272 A [0101]
- US 4172120 A [0101]
- US 4252790 A [0101]
- US 4340585 A [0101]
- US 4814354 A [0101]
- US 4874744 A [0101]
- US 4895723 A [0101]
- US 5695749 A [0101]
- US 6066336 A [0101]
- US 5693675 A [0102]
- US 5607669 A [0102]
- WO 0038725 A [0114]
- US 5767115 A [0114]
- EP 129748 A [0114]
- GB 2184122 A [0114]
- US 4929629 A [0114]
- WO 0112187 A [0118]
- WO 0112612 A [0118]
- WO 9962870 A [0118]
- WO 9962872 A [0118]
- WO 9962871 A [0118]
- WO 9857941 A [0118]
- WO 0140170 A [0118]
- US 3342810 A [0123]
- WO 3022286 A [0156] [0160] [0162] [0164] [0166] [0168] [0170] [0172] [0174] [0176] [0178] [0180]
- WO 0250051 A [0182]

Non-patent literature cited in the description

- *Science*, 1998, vol. 282, 751-54 [0114]
- *J Med Chem*, 1996, vol. 39, 665 [0118]
- *Expert Opinion on Therapeutic Patents*, vol. 10 (5), 623-634 [0118]
- *J Med Chem*, 2000, vol. 43, 527 [0118]
- **REMINGTON**. The Science and Practice of Pharmacy. Mack Publishing Company, 1995 [0135]
- **HOOVER, JOHN E.** Remington's Pharmaceutical Sciences. Mack Publishing Co, 1975 [0135]
- Pharmaceutical Dosage Forms. Marcel Decker, 1980 [0135]
- Pharmaceutical Dosage Forms and Drug Delivery Systems. Lippincott Williams & Wilkins, 1999 [0135]
- Remington's Pharmaceutical Sciences. 2000 [0139] [0140]
- *CHEMICAL ABSTRACTS*, 9063-87-0 [0141]
- *CHEMICAL ABSTRACTS*, 25086-15-1 [0141]
- *CHEMICAL ABSTRACTS*, 25212 - 88 - 8 [0193]
- *CHEMICAL ABSTRACTS*, 26936 - 24 - 3 [0195]
- *CHEMICAL ABSTRACTS*, 123-94-4 [0197]

SZABADALMI IGÉNYPONTOK

1. A (II) általános képletű vegyület



(II) általános képlet

amelyben

M jelentése CH_2 - vagy NH -csoport;

R^1 jelentése hidrogénatom vagy hidroxil-csoport;

- 10 R^2 jelentése hidrogénatom, CH_3 -, $-\text{CH}_2\text{CH}_3$ -, $-\text{CH}_2\text{CH}_2\text{CH}_3$ -, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ -, $-\text{CH}(\text{CH}_3)_2$ -, $-\text{CH}_2\text{CH}(\text{CH}_3)_2$ -, $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ -, $-\text{CH}_2\text{OH}$ -, $-\text{CH}_2\text{OCH}_3$ -, $-\text{CH}(\text{OH})\text{CH}_3$ -, $-\text{CH}_2\text{SCH}_3$ -, vagy $-\text{CH}_2\text{CH}_2\text{SCH}_3$ -csoport;

vagy ezek gyógyászatiilag elfogadható sója,

egy májbetegség megelőzésében és/vagy kezelésében történő alkalmazásra,

- 15 amely májbetegséget a következő csoportból választhatjuk ki: Alagilles szindróma (ALGS), progresszív familiáris intrahepatikus kolestázis (PFIC), primer biliáris cirrhosis (PBC), primer szklerotizáló cholangitis (PSC), és epepangásos májbetegség viselkedése.

- 20 2. A vegyület 1. igénypont szerinti alkalmazása, ahol a (II) általános képletű vegyületet a következő csoportból választjuk ki:

1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N-(karboximetil)karbamoil]benzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin;

- 25 1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N'-((S)-1-karboxietil)karbamoil]benzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,5-benzotiazepin;

1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N-((S)-1-karboxipropil)karbamoil]benzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin;

1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N-((R)-1-karboxi-2-etiltioetil)karbamoil]benzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin;

1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N-((S)-1-karboxipropil)karbamoil]-4-hidroksibenzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin;

1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N-((R)-1-karboxi-2-metiltioetil)karbamoil]-4-hidroksibenzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin;

1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N-((S)-1-karboxi-2-metilpropil)karbamoil]benzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin;

1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-(R)- α -[N-((S)-1-karboxi-2-(R)-hidroksipropil)karbamoil]-4-hidroksibenzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin;

1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N-((S)-1-karboxibutil)karbamoil]-4-hidroksibenzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin;

1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N-((S)-1-karboxietil)karbamoil]benzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin;

1,1-dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N'-((S)-1-karboxipropil)karbamoil]-4-hidroksibenzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,5-benzotiazepin;

1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N-((S)-1-karboxietil)karbamoil]-4-hidroksibenzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin;

1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N-((S)-1-karboxi-2-metilpropil)karbamoil]-4-hidroksibenzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin; és

1,1-Dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)-1'-fenil-1'-[N'-(karboximetil)karbamoil]metil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,5-benzotiazepin

vagy ezek gyógyászatilag elfogadható sója.

3. A vegyület 1. vagy 2. igénypont szerinti alkalmazása ahol a (II) általános képletű vegyület 1,1-dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N-((S)-1-karboxipropil)karbamoil]benzil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin, vagy ennek gyógyászatilag elfogadható sója.

4. A vegyület 1. vagy 2. igénypont szerinti alkalmazása ahol a (II) általános képletű vegyület 1,1-dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)-1'-fenil-1'-[N'-(karboximetil)karbamoil]metil)karbamoilmetoxi)-2,3,4,5-tetrahidro-1,5-benzotiazepin, vagy ennek gyógyászatilag elfogadható sója.

5. A vegyületnek az 1-6. igénypontok bármelyike szerinti alkalmazása, ahol a májbetegség Alagilles szindróma.

6. A vegyületnek az 1-6. igénypontok bármelyike szerinti alkalmazása, ahol a májbetegség progresszív familiáris intrahepatikus kolestázis (PFIC).

7. A vegyületnek az 1-6. igénypontok bármelyike szerinti alkalmazása, ahol a májbetegség primer biliáris cirrhosis (PBC).


8. A vegyületnek az 1-6. igénypontok bármelyike szerinti alkalmazása, ahol a májbetegség primer szklerotizáló cholangitis (PSC).

9. A vegyületnek az 1-6. igénypontok bármelyike szerinti alkalmazása, ahol a májbetegség epepangásos májbetegség viszketegsége.

10. Gyógyászati készítmény, amely a (II) általános képletű vegyületet tartalmazza

4

EP2637668




(II) általános képlet

ahol

- 5 M jelentése CH_2 - vagy NH-csoport;
 R^1 jelentése hidrogénatom vagy hidroxil-csoport;
 R^2 jelentése hidrogénatom, CH_3 -, $-\text{CH}_2\text{CH}_3$ -, $-\text{CH}_2\text{CH}_2\text{CH}_3$ -, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ -,
 $\text{CH}(\text{CH}_3)_2$ -, $-\text{CH}_2\text{CH}(\text{CH}_3)_2$ -, $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ -, $-\text{CH}_2\text{OH}$ -, $-\text{CH}_2\text{OCH}_3$ -,
 $\text{CH}(\text{OH})\text{CH}_3$ -, $-\text{CH}_2\text{SCH}_3$ -, vagy $-\text{CH}_2\text{CH}_2\text{SCH}_3$ -csoport;
 10 vagy ezek gyógyászatilag elfogadható sója,
 egy májbetegség megelőzésében és/vagy kezelésében történő alkalmazásra,
 amely májbetegséget a következő csoportból választatjuk ki: Alagilles szindróma
 (ALGS), progresszív familiáris intrahepatikus kolestázis (PFIC), primer biliáris cir-
 rhosis (PBC), primer szklerotizáló cholangitis (PSC), és epepangásos májbetegség
 15 viszketisége.
11. A 10. igénypont szerinti gyógyászati készítmény, amelyben a (II) ál-
 talános képletű vegyület 1,1-dioxo-3,3-dibutyl-5-fenil-7-metiltio-8-(N-((R)-α-[N-((S)-
 1-karboxipropil)karbamoyl]benzil)karbamoylmetoxi)-2,3,4,5-tetrahidro-1,2,5-
 20 benzotiazepin vagy ennek gyógyászatilag elfogadható sója.
12. A 10. igénypont szerinti gyógyászati készítmény, amelyben a (II) ál-
 talános képletű vegyület 1,1-dioxo-3,3-dibutyl-5-fenil-7-metiltio-8-(N-((R)-1'-fenil-1'-
 [N'-(karboximetil)karbamoyl]metil)karbamoylmetoxi)-2,3,4,5-tetrahidro-1,5-
 25 benzotiazepin vagy ennek gyógyászatilag elfogadható sója.
13. Gyógyszerészeti kombináció szimultán vagy szekvenciális
 beadásra, amely egy (II) általános képletű vegyületet

5

EP2637668



(II) általános képlet

ahol

M jelentése CH_2 - vagy NH -csoport;5 R^1 jelentése hidrogénatom vagy hidroxil-csoport;


R^2 jelentése hidrogénatom, CH_3 -, $-\text{CH}_2\text{CH}_3$ -, $-\text{CH}_2\text{CH}_2\text{CH}_3$ -, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ -, $-\text{CH}(\text{CH}_3)_2$ -, $-\text{CH}_2\text{CH}(\text{CH}_3)_2$ -, $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ -, $-\text{CH}_2\text{OH}$ -, $-\text{CH}_2\text{OCH}_3$ -, $-\text{CH}(\text{OH})\text{CH}_3$ -, $-\text{CH}_2\text{SCH}_3$ -, vagy $-\text{CH}_2\text{CH}_2\text{SCH}_3$ -csoport;

vagy ezek gyógyászatilag elfogadható sóját,

10 és ursodezoxikólsavat tartalmaz, egy májbetegség megelőzésében és/vagy kezelésében történő alkalmazásra, amely májbetegséget a következő csoportból választhatjuk ki: Alagilles szindróma (ALGS), progresszív familiáris intrahepatikus kolektázis (PFIC), primer biliáris cirrhosis (PBC), primer szklerotizáló cholangitis (PSC), és epepangásos májbetegség viszketegsége.

15

14. gyógyszerészeti kombináció szimultán vagy szekvenciális beadásra, amely egy (II) általános képletű vegyületet



(II) általános képlet

20 ahol

M jelentése CH_2 - vagy NH -csoport; R^1 jelentése hidrogénatom vagy hidroxil-csoport;

R^2 jelentése hidrogénatom, CH_3 -, $-\text{CH}_2\text{CH}_3$ -, $-\text{CH}_2\text{CH}_2\text{CH}_3$ -, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ -, $-\text{CH}(\text{CH}_3)_2$ -, $-\text{CH}_2\text{CH}(\text{CH}_3)_2$ -, $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ -, $-\text{CH}_2\text{OH}$ -, $-\text{CH}_2\text{OCH}_3$ -, $-\text{CH}(\text{OH})\text{CH}_3$ -, $-\text{CH}_2\text{SCH}_3$ -, vagy $-\text{CH}_2\text{CH}_2\text{SCH}_3$ -csoport,

vagy ezek gyógyászatilag elfogadható sóját,

- 5 és nor-ursodezoxikólsavat tartalmaz, egy májbetegség megelőzésében és/vagy kezelésében történő alkalmazásra, amely májbetegséget a következő csoportból választhatjuk ki: Alagilles szindróma (ALGS), progresszív familiáris intrahepatikus kolestázis (PFIC), primer biliáris cirrhosis (PBC), primer szklerotizáló cholangitis (PSC), és epepangásos májbetegség viszketegsége.

10

- 15 15. A gyógyszerészeti kombináció 13. vagy 14. igénypont szerinti alkalmazása, amelyben a (II) általános képletű vegyület 1,1-dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)- α -[N-((S)-1-karboxipropil]karbamoil]benzil]karbamoilmetoxi)-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepin vagy ennek gyógyászatilag elfogadható sója.

- 20 16. gyógyszerészeti kombináció 13. vagy 14. igénypont szerinti alkalmazása, amelyben a (II) általános képletű vegyület 1,1-dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-((R)-1'-fenil-1'-[N'-(karboximetil)karbamoil]metil]karbamoilmetoxi)-2,3,4,5-tetrahidro-1,5-benzotiazepin vagy ennek gyógyászatilag elfogadható sója.
-